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Abstract
Background: The diagnosis of asthma in young children is based mostly on symptoms.
The need for objective methods for diagnosing asthma in this age group is therefore
obvious. Lung function in preschool children can be assessed with impulse oscillometry
(IOS), which involves no voluntary breathing manoeuvers. Because most children with
asthma have normal baseline lung function, the use of bronchoprovocative tests may
improve diagnostics. Fractional concentration of nitric oxide (FeNO) is suggested to be a
good measure for airway inflammation, and the method is also available for preschoolers.
Aims: To examine new methods for evaluating airway hyperresresponsiveness and
inflammation in young children. Further aims were to study the effect of parental smoking
on lung function and airway inflammation in wheezy children and whether children with
severe exercise induced bronchoconstriction exhibit small airways dysfunction.
Methods: A total of 272 children (3 to 8 years old), 231 with obstructive syndromes and
41 healthy controls, were examined. Children with various clinical characteristics were
recruited: troublesome lung symptoms, a history of bronchopulmonary dysplasia (BPD),
early wheezing symptoms and multiple-trigger wheezing. Airway hyperresponsiveness
was evaluated with exercise test, methacholine and mannitol challenge tests using IOS.
FeNO measurements with two different analyzers were examined. Parental reports and
children’s urinary cotinine measurements served to monitor exposure to environmental
tobacco smoke.
Results: Exercise test with IOS succesfully identified children with probable asthma, and
the methacholine challenge test was able to differentiate children with probable asthma,
BPD and early wheezing from the controls. The mannitol challenge test, however, was
unable to distinguish between the study groups. Furthermore, children with severe
exercise-induced bronchoconstriction (EIB) exhibited small airways dysfunction. A
portable FeNO analyzer proved to be more difficult than a stationary device to use in
young children. In addition, its poorer accuracy in low FeNO levels diminishes its
feasibility in this age group. However, a portable analyzer differentiated children with
asthma from the controls. Children with smoking mothers had poorer lung function and
higher FeNO than children with non-smoking mothers. Urinary cotinine concentrations
closely reflected reported smoking in the family. A father’s smoking had no effect on
children’s FeNO or lung function.
Conclusions: The exercise test with IOS succesfully identified children with probable
asthma. The methacholine challenge test aids in evaluating airway hyperresponsiveness in
young children, although its cut-off value for this age group requires re-evaluation. A
portable FeNO analyzer can also serve as a screening tool in young children, because it
differentiates asthmatics from the controls with reasonable accuracy. Children with severe
exercise induced bronchoconstriction exhibited small airways dysfunction, which suggests
that peripheral airways are involved even in young asthmatic children. Maternal smoking
clearly deteriorates lung function and increases bronchial inflammation in young children
with wheeze. This objective finding with cotinine measurements emphasizes current
knowledge; young children should not be exposed to environmental tobacco smoke.
Tiivistelmä
Tausta: Pienillä lapsilla on paljon hengitystieoireita. Hengitysoireiden selvittely ja
astmadiagnostiikka tässä ikäryhmässä perustuu enimmäkseen oireiden tulkintaan ja
riskitekijöiden kartoitukseen. Leikki-ikäisen lapsen keuhkojen toimintaa voidaan tutkia
oskillometrialla, joka ei vaadi lapselta suurta yhteistyökykyä. Valtaosalla astmaa
sairastavista lapsista on normaali keuhkojen toiminta perustilassa, jolloin diagnostiikka
voi täsmentyä keuhkoputkien supistumistaipumuksen määrityksellä. Uloshengityksen
typpioksidipitoisuutta mittaamalla voidaan arvioida keuhkoputkien astmaattista
tulehdusta. Erilaiset ärsykkeet, kuten tupakansavulle altistuminen, voivat vaikuttaa lapsen
hengitysteiden astmaattiseen tulehdukseen ja keuhkojen toimintaan.
Tavoitteet: Selvittää uusien menetelmien toimivuutta leikki-ikäisen lapsen keuhkoputkien
supistumisherkkyyden ja astmaattisen tulehduksen arvioinnissa. Lisäksi tavoitteena oli
tutkia vanhempien tupakoinnin vaikutusta lapsen keuhkojen toimintaan.
Menetelmät: Tutkimukseen osallistui 272 (3-8-vuotiasta) lasta, joista 231 oli
hengitystieoireisia ja 41 terveitä verrokkeja. Tutkimukseen osallistui astmaepäilyn vuoksi
selvityksiin lähetettyjä, vastasyntyneenä bronkopulmonaalisen dysplasian (keskosen
keuhkosairaus) sairastaneita sekä alle 2-vuotiaana toistuvista hengitysvaikeuksista
kärsineitä lapsia. Keuhkoputkien supistumistaipumusta tutkittiiin ulkojuoksukokeella sekä
metakoliini- ja mannitolialtistustestillä. Keuhkojen toiminta määritettiiin oskillometrialla.
Keuhkoputkien astmaattista tulehdusta arvioitiin uloshengityksen tyypioksidipitoisuutta
mittaamalla kahdella eri laitteella. Tupakansavulle altistumista monitoroitiin vanhempien
täyttämällä kyselykaavakkeella sekä lasten virtsan kotiniinimäärityksellä.
Tulokset: Ulkojuoksukoe oskillometriaseurannassa erotteli hyvin astmaoireista kärsineet
lapset muista ryhmistä. Metakoliinialtistustesti osoitti keuhkoputkien supistumista
kahdella kolmasosalla kaikista tutkituista lapsista, mutta hengitysoireista kärsineet lapset
olivat sille herkempiä kuin kontrollilapset. Mannitolialtistustesti ei erotellut ryhmiä
toisistaan. Lapsilla, joilla oli vaikein rasituksen aiheuttama keuhkoputkien
supistumistaipumus, oli myös poikkeavuutta pienten ilmateiden toiminnassa.
Uloshengityksen typpioksidin mittaaminen on vaikempaa kannettavalla mittarilla kuin
isommalla laitteella, ja myös laitteen huonompi tarkkuus matalilla pitoisuuksilla rajoittaa
sen käyttöä pienillä lapsilla. Tupakoivien äitien lapsilla oli huonompi keuhkojen toiminta
ja enemmän keuhkoputkien astmaattista tulehdusta kuin tupakoimattomien äitien lapsilla.
Isien tupakoinnilla ei ollut samanlaista vaikutusta lasten keuhkojen toimintaan. Virtsan
kotiniinipitoisuudet kuvasivat hyvin vanhempien ilmoittamaa tupakointia kotona.
Johtopäätökset: Ulkojuoksukoe yhdistetty oskillometriatutkimukseen on hyvä tutkimus
leikki-ikäisen astmaoireiden selvittelyssä. Metakoliinialtistus on tämän tutkimuksen
mukaan toimiva menetelmä keuhkoputkien supistumistaipumuksen selvittelyssä, mutta
pienten lasten viitearvojen puuttuminen rajoittaa sen käyttöä tässä ikäryhmässä.
Kannettavaa uloshengityksen typpioksidimittaria voidaan käyttää seulontamielessä myös
pienillä lapsilla. Äitien tupakointi huonontaa astmaoireista kärsivien lasten keuhkojen
toimintaa ja lisää keuhkoputkien astmaattista tulehdusta. Tämä objektiivinen löydös
vahvistaa käsitystä, että pienen lapsen ei tulisi altistua tupakansavulle.
7Contents
Abstract 5?
Tiivistelmä 6?
Contents 7?
List of original publications 11?
Abbreviations 12?
1 Introduction 14?
2 Review of the literature 16?
2.1 Obstructive respiratory symptoms in early childhood 16?
2.1.1 Phenotypes of preschool wheezing 16?
2.1.2 Bronchopulmonary dysplasia and lung function in early childhood 22?
2.2 Risk factors for childhood asthma 23?
2.2.1 Family history / genetics 23?
2.2.2 Infections 24?
2.2.3 Environmental factors 26?
2.2.3.1 Environmental tobacco smoke 27?
2.3 Diagnosing asthma in preschool children 31?
2.4 Measuring lung function in young children 33?
2.4.1 Impulse oscillometry 34?
2.4.1.1 Technique 34?
2.4.1.2 Clinical applications in young children 35?
2.4.2 Airway hyperresponsiveness assessment 37?
2.4.2.1 Direct challenges 38?
2.4.2.2 Indirect challenges 40?
2.4.3 Measuring small airway function 44?
82.4.3.1 Small airways and IOS in children 45?
2.5 Airway inflammation 45?
2.5.1 Fractional concentration of nitric oxide (FeNO) 46?
2.5.1.1 Biology of FeNO in the airways 46?
2.5.1.2 FeNO measurement 47?
2.5.1.3 Factors affecting FeNO 48?
2.5.1.4 FeNO and young children 50?
3. Aims of the study 52?
4. Materials and methods 53?
4.1 Study subjects 53?
4.2 Lung function and airway hyperresponsiveness assessments 55?
4.2.1 Lung function 55?
4.2.2 Airway hyperresponsiveness assessment 56?
4.2.2.1 Exercise test 56?
4.2.2.2 Methacholine challenge test 56?
4.2.2.3 Mannitol challenge test 57?
4.3 FeNO measurements 57?
4.4 Urinary cotinine measurements 58?
4.5 Atopy assessment 58?
4.6 Eosinophilic activity 58?
4.7 Statistical analysis 59?
4.8 Ethics 60?
5. Results 61?
5.1 FeNO measurements (Study I) 61?
5.1.1 FeNO measurements with stationary and portable analyzers 61?
5.2 Environmental tobacco smoke (Study II) 63?
95.2.1 Exposure to parental tobacco smoke 63?
5.2.2 Parental reports and cotinine concentrations 64?
5.2.3 FeNO level and exposure to tobacco smoke 65?
5.2.4 Exposure to tobacco smoke and lung function 66?
5.2.5. Skin prick test positivity in relation to tobacco smoke exposure 67?
5.3 Airway hyperresponsivess (Study III) 68?
5.3.1 Baseline lung function 68?
5.3.2 Exercise test 68?
5.3.3 Methacholine challenge test 69?
5.3.4 Mannitol challenge test 70?
5.3.5 FeNO, atopy and AHR tests 70?
5.3.6 Multivariate analysis 72?
5.4 Small airway function (Study IV) 72?
5.4.1 Baseline lung function 72?
5.4.2 Methacholine challenge test 72?
5.4.3 IOS parameters after the methacholine challenge test 73?
6. Discussion 76?
6.1 Methodological considerations 76?
6.1.1 Study populations 76?
6.1.2 Lung function, airway hyperresponsiveness and FeNO measument 77?
6.2.3 ETS monitoring 78?
6.2 Discussion of the main results 78?
6.2.1 FeNO measurement with two analyzers in young children 78?
6.2.2 Exposure to tobacco smoke and respiratory health in preschool-age
multiple-trigger wheezers 79?
6.2.3 Airway hyperresponsiveness 82?
10
6.2.4 Small airways function in relation to asthma severity 85?
7. Future considerations 88?
8. Conclusions 89?
9. Acknowledgements 90?
10. References 92?
11
List of original publications
This thesis is based on the following publications:
I Kalliola  S,  Malmberg  P,  Rito  T,  Pelkonen  AS,  Mäkelä  MJ.  Can  we  use
portable nitric oxide analyzer in young children? Pediatr Pulmonol 2011;
46:627-31.
II Kalliola S, Pelkonen AS, Malmberg LP, Sarna S, Hämäläinen M, Mononen
I,  Mäkelä  MJ.  Maternal  smoking  affects  lung  function  and  airway
inflammation in young children with multiple-trigger wheeze. J Allergy Clin
Immun 2013: 131(3):730-5.
III Kalliola S, Malmberg LP, Kajosaari M, Mattila PS, Pelkonen AS, Mäkelä
MJ. Assessing direct and indirect airway hyperresponsiveness children using
impulse oscillometry. Ann Allergy Asthma Immunol 2014: 113(2):166-72.
IV Kalliola S, Malmberg LP, Pelkonen AS, Mäkelä MJ. Small airways
dysfunction during induced bronchoconstriction in young children.
Submitted.
The publications are referred to in the text by their Roman numerals. The original articles
are reprinted with the kind permission of the copyright holders.
12
Abbreviations
AHR airway hyperresponsiveness
AMP adenosine monophosphate
API asthma predictive index
ATS American Thoracic Society
AUC area under curve
AX reactance area
BAL bronchoalveolar lavage
BPD bronchopulmonary dysplasia
CI confidence interval
COPD chronic obstructive pulmonary disease
CV coefficient of variability
ECP eosinophilic cationic protein
EIB exercise-induced bronchoconstriction
ELISA enzyme-linked immunosorbent assay
ERS European Respiratory Society
ETS environmental tobacco smoke
EVH eucapnic voluntary hyperpnea challenge
EW early wheezer
FeNO fractional concentration of nitric oxide
FEV1 forced expiratory volume in one second
FOT forced oscillation technique
Fres resonance frequency
FVC forced vital capacity
GWAS genome-wide association study
HRCT high-resolution computer tomography
HRV human rhinovirus
Hz Hertz
ICON International consensus on pediatric asthma
IgG immunoglobulin G
IgE immunoglobulin E
IL interleukin
INF? interferon gamma
IOS impulse oscillometry
MBW multiple-breath washout
MBNW multiple-breath nitrogen washout
MEF25-75 mean expiratory flow between 25% and 75% of vital capacity
MEF50 mean expiratory flow at 50% of vital capacity
NO nitric oxide
NOS nitric oxide synthase
cNOS constitutive nitric oxide synthase
iNOS inducible nitric oxide synthase
OR odds ratio
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PCR polymerase chain reaction
PD20FEV1 provocative dose to induce a 20% decrease in FEV1
PD40R5 provocative dose to induce a 40% increase in R5
PEF peak expiratory flow
PIF peak inspiratory flow
PNEC pulmonary neuroendocrine cells
ppb parts per billion
R5 resistance at 5 Hz
R20 resistance at 20 Hz
R5-20 difference between R5 and R20
RIA radioimmunoassay
Rint interrupter resistance
ROC receiver-operator characteristics
Rrs resistance
RSV respiratory syncytial virus
SPT skin prick test
sRaw specific airway resistance
TNF-? tumor necrosis factor beeta
TLC total lung capacity
TLS troublesome lung symptoms
X5 reactance at 5 Hz
X10 reactance at 10 Hz
Xrs reactance
Zrs impedance
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1 Introduction
Wheezing in early childhood is common, but the underlying pathologies are
heterogeneous. A viral infection is the most frequent cause of preschool wheezing, and up
to 50% of all children wheeze at least once before their sixth birthday (1). Considering the
high prevalence of wheezing, the symptom is an important health care issue worldwide.
Researchers have proposed several wheezing phenotypes for preschool wheezing based on
the large cohort studies. Transient, late-onset and persistent phenotypes are characterized
according to the patient’s age at onset and the duration of the symptoms (2). The temporal
pattern of the symptom indicates the wheeze type: episodic (viral) and multiple-trigger (3).
Episodic wheezers wheeze only during the viral infections, whereas multiple-trigger
wheezers wheeze both during and outside descrete episodes. Both infections and other
triggers such as allergens, tobacco smoke exposure and exercise can cause symptoms for
multiple-trigger wheezers. However, wheezing phenotypes offer only modest help in the
evaluating of preschool children, because the analysis is based on the retrospective
studies. In addition, children frequently move from one phenotype to another during the
preschool years and more than half of these children stop wheezing before they start
school (1). Many children who had suffered bronchopulmonary dysplasia (BPD) also
experience respiratory symptoms during their childhood, symptoms that may mimic
asthma (4). Consequently, finding children who benefit from asthma medication and
require follow-up in this large group of wheezers is challenging.
Some of the wheezers develop asthma, which is characterized by bronchial
inflammation and airway hyperresponsiveness. Asthma diagnosis is based on assessment
of lung function in school-age children and adults, but assessing lung function in
preschoolers may be challenging. Impulse oscillometry (IOS) however, requires no
voluntary breathing manoeuvers and over 80% of preschool-age children can perform it
successfully (5). Assessing of airway hyperresponsiveness (AHR) with IOS may aid in
evaluation of respiratory symptoms, because most of the mild and moderate asthmatic
children exhibit normal baseline lung function. AHR can be assessed with direct and
indirect challenge tests. Direct tests are highly sensitive but less specific for asthma.
Methacholine is thought to act directly on smooth muscle cells in the bronchi and is
widely used to exclude asthma (6). Indirect challenge tests, such as exercise and mannitol
challenges, act through mediators, which are released by eosinophils, mast cells and
neuronal cells (7). Based on their mechanism of action these tests are associated with
bronchial inflammation, unlike direct tests, which are considered to be rather independent
from inflammation. Indirect tests are therefore thought to be more specific than direct tests
in diagnosing asthma.
The fractional concentration of nitric oxide (FeNO) is suggested to reflect airway
inflammation (8). The method is both noninvasive and available to young children. A
conventional, stationary device is available mostly in specialized clinics, but a portable,
hand-held device can also be used ouside of these centers. Some have suggested that the
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hand-held device is more difficult to use than the older device, whether this device is
suitable for young children remains unknown.
Recently, research has linked small airways dysfunction to severe asthma. Researchers
have proposed the IOS parameter R5-20 as a measure for small airways function (9).
Others have also suggested that, when it comes to their peripheral airways, asthmatics
respond in distinct ways to bronchoprovocative tests. Small airways dysfunction during
methacholine challenge has been associated with severe asthma in adults (10). Knowledge
of the peripheral airways function in young children is scarce.
Exposure  to  environmental  tobacco  smoke  (ETS)  is  a  well-known  risk  factor  for
childhood respiratory symptoms. ETS is also known to decrease lung function (11), but
little is known about its effects on bronchial inflammation. Parental reports often monitore
smoking at home, but measuring of cotinine levels in body fluids and hair offers a more
objective method for estimating ETS (12).
Diagnosing asthma in young children is usually based on symptoms.  The aim of this
study was to evaluate new methods for determing objective airway hyperresponsiveness
and assessing bronchial inflammation in young children. We used impulse oscillometry to
study direct and indirect airway hyperresponsiveness tests; we specially inquired whether
these tests could differentiate various patient groups from one another. We used IOS
parameters reflecting peripheral airways function to examine small airways function in
relation to asthma severity. In addition, we investigated the feasibility of a portable FeNO
analyzer in young children. Finally, we studied the effect of parental smoking on
children’s lung function and airway inflammation.
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2 Review of the literature
2.1 Obstructive respiratory symptoms in early childhood
Respiratory symptoms in the early years of life are extremely common. Typical
obstructive symptoms in preschool children include recurrent cough, difficulty in
breathing, chest tightness and wheezing (13). Large population studies have revealed that
approximately one third of all children have at least one wheezing episode before the age
three (2,14,15). Cohort studies indicate that the cumulative prevalence of wheezing during
the first six years of life is 16-49% (2,16-24). Wheezing may result from number of
conditions, but most wheezing episodes are associated with viral infections, which occur
frequently in young children. Considering the high prevalence of wheezing in preschool
children, the problem is a serious health care issue worldwide (14). Although the
understanding of preschool wheezing has improved, our management of wheezing
disorders remains challenging.
2.1.1 Phenotypes of preschool wheezing
Several large population-based studies have deepened our understanding of early
obstructive symptoms and classification of wheezy children into distinct phenotypes.
Table 1 shows basic data and the prevalence of preschool wheezing phenotypes in ten
cohort studies.
The landmark study of wheezing disorders in young children, the Tucson Children’s
Respiratory Study in Arizona, followed 826 children from birth to the age of six years (2).
The participitants in this cohort study were enrolled between 1980 and 1984. The children
were investigated in their infancy, as well as at ages three and six. Assessment included
IgE measurement, lung function testing, skin prick tests and questionnaires completed by
the children’s parents. The children in this study were divided into never wheezers
(51.5%), transient early wheezers (19.9%, stopped wheezing before the age of 3), late-
onset wheezers (15%, bagan wheezing after 3 years of age) and persistant wheezers
(13.7%, wheezed both before and after 3 years of age) based on their age at onset and the
duration of their symptoms (2) (Table 1).
The children of the Tucson cohort underwent further analysis at 11 years of age (25),
which included peak expiratory flow (PEF), the methacholine challenge test, skin prick
testing and serum IgE. Transient early wheezing was independent of airway
hyperresponsiveness, and non-atopic wheezing in toddlers and young schoolers was
associated with PEF variability, but not with a positive methacholine test result. IgE-
associated wheezing/asthma was associated with persistent wheezing at any age, male sex,
airway hyperresponsiveness to methacholine, PEF variability and positive atopy markers.
The children of the Tucson cohort are still being followed up. Their follow-up data at 22
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years of age indicated that asthma onset at 6 years, persistent wheezing in early life,
sensitization to Alternaria alternata, reduced lung function and airway hyperresponsivenss
at 6 years were independent risk factors for chronic asthma at the age of 22 (26).
The German Multicentre Allergy Study (MAS) followed 1314 children annually from
birth to seven years of age (16). The overall wheeze prevalence was 35% (Table 1). The
researchers found that children with wheezing episodes during only the first three years of
life  showed  slight  impairment  in  lung  function  at  seven  years  of  age.  Children  with
persistent or late-onset wheezing, however, showed a significant decrease in expiratory
flow volumes at seven years of age. This study indentifies several risk factors for lung
function impairment in persistent wheezers: a history of parental atopy, time in years since
the first wheeze episode, sensitization to indoor allergens, elevated cord IgE and a low
ponderal index at birth (16). Maternal smoking was more common in all groups of
wheezers than in the group in which children never wheezed (16).
A British cohort study (Isle of Wight) investigated 1456 children at 1, 2, 4 and 10
years of age to determine the natural history of childhood wheezing (21). Of these children
40% wheezed at least once before the age of 10, half of the wheezers were early transient
wheezers,  30% were  persistent  wheezers  and  19% late-onset  wheezers  (Table  1).  In  this
study, 37% of early wheezers (onset before 4 years of age) continued to wheeze at the age
of 10. These persistent wheezers had more physician-dignosed asthma before two years of
age, hospital admissions, special referrals and use of inhaled corticosteroids than did
transient early wheezers. In addition, they were more reactive to methacholine than were
transient wheezers. Both groups had lower lung function at the age of ten years than did
never-wheezers. Late-onset wheezers had a similar airway hyperresponsiveness pattern to
that of early wheezers (21).
The ALSPAC study, another British cohort, used annual questionnaires to follow 6265
children from birth to age seven (18). The study assessed the children’s lung function,
AHR and atopy at seven to nine years of age. This large cohort revealed six different
wheezing phenotypes (Table 1) and an overall wheezing prevalence of 41% (18).
Repeated symptom-based evaluation yielded a novel intermediate-onset phenotype with
onset after 18 months of age. The study also found a strong association between
intermediate phenotype and atopy and AHR (18). The PIAMA study from the Netherlands
also gathered annual data (22,27,28). This latter study reported similar findings to the
ALSPAC study regarding phenotypes of preschool wheezing. However, the prevalence of
wheezing was lower than in ALSPAC study (25%) (22). The PIAMA study had complete
follow-up data on 2180 neonates until eight years of age (22) (Table 1). The MAAS
cohort from the UK examined preschool wheezing in 1085 children (17,29-31). Of these
children, 840 attended the five-year follow-up visit. The children were evaluated at 3, 5, 8
and 11 years of age. The overall prevalence of wheezing at preschool age was 44% and
around half of all wheezers were categorized into the transient phenotype (17) (Table1).
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Three large Scandinavian investigations have explored these questions. The ECA
study from Norway recruited 3754 newborns and distributed questionnaires to their
parents every six months until the newborn reached the age of two in order to evaluate
their symptoms (20,32,33). Lung function was assessed at infancy, at 10 and 16 years of
age. The researchers assessed high prevalence of never wheezers (69%) (20) (Table 1).
The BAMSE study from Sweden used more stringent criteria for asthma/wheezing than
did other studies with other cohorts, reporting the lowest prevalence of these cohorts
(16%) (23) (Table 1). The COPSAC study from Denmark focused on troublesome lung
symptoms rather than wheezing and found a symptom prevalence of 46% (34) (Table 1).
These children were born to atopic mothers and were considered to be at high risk for
atopic diseases. The study suggested that a quantitative measure of troublesome lung
symptoms during the first three years of life is a better predictor of asthma than the
observation of wheeze (35). In the final analysis the total number of acute clinic visits for
asthma symptom was associated with later asthma, but the wheezing was not(35).
The PASTURE study evaluated effects of living on a farm on allergic diseases among
a large birth cohort drawn from five European countries: Austria, France, Germany,
Switzerland and Finland (24). The study investigated wheezing by distributing annual
questionnaires to the caregivers of 953 children until they reached the age of six. The
prevalence  of  wheezing  in  this  cohort  was  30%,  the  most  common  phenotype  of  which
was transient wheezing (16.8%) (Table 1) (24). Unremitting wheeze was suggested as
promising alternative asthma definition for epidemiologic studies.
Further attempts to clarify heterogeneous wheezing phenotypes in young children have
resulted in recently published reports (36). A French study analyzed 20 variables among
551 wheezy children younger than 36 months (37) and identified three clusters of wheezy
young children: mild episodic viral wheezers (59%), nonatopic uncontrolled wheezers
(despite of high doses of inhaled corticosteroids) (29%) and multiple-trigger wheezers
with eczema and increased spesific IgE levels (12%). Atopic multiple-trigger wheezing
was associated with allergenic factors, male sex, and uncontrolled nonatopic wheezing
with infectious factors such as day care attendance and female sex (37). A British birth
cohort study of 1184 children revealed a novel group of persistent troublesome wheezers
(3.2% of the cohort children) (38) that suffered substantially more exacerbations,
hospitalizations and unscheduled health care visits than did all other groups.
The European Respiratory Society (ERS) Task Force proposed somewhat different
phenotyping system in 2008 by suggesting the definitions ‘episodic’ (viral) and ‘multiple-
trigger wheezing’ to describe different phenotypes of preschool wheezing (3). Episodic
(viral) wheezing refers to those children who wheeze intermittently during the viral
infections but are well between the episodes. Multiple-trigger wheezers wheeze both
during and outside discrete episodes. An episodic pattern is usually caused by viral
infections, declines over the time and disappears by the age of six, but may continue into
school age as episodic wheezing, change to multiple-trigger wheezing or disappear later in
life  (3).  If  other  than  viral  triggers,  such  as  allergen  exposure  or  environmental  tobacco
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smoke, cause wheezing in a preschooler, the ERS Task Force suggests the definition of
‘multiple-trigger wheezing’ and recommended caution with the term ‘asthma’ in
preschool-age children (3) based on the heterogeneity of the symptom entity.
Many of the cohort studies have suffered from substantial loss of the children’s
participation in follow-up (39). The largest cohorts (ASLPAC and PIAMA) saw the
highest  numbers  of  phenotypes  (six  and  five,  respectively)  (22).  These  two  studies  also
evaluated symptoms on an annual basis. The Tucson study examined children at infancy,
as well as at three and six years of age (2). Most of these studies used population-based
birth cohorts, but an exception is the COPSAC study, which enrolled children with atopic
mothers (40). Different diagnostic methods in the BAMSE study resulted in a low
prevalence of wheezing (23).
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Cohort Patients Methods Wheezing phenotypes Other outcomes
Tucson study,
Tucson,
Arizona,USA (2)
Recruitment 1980-84
1246 newborns
population based cohort
826 followed up to 6 years
Cord serum IgE (n=750)
Lung function at infancy (176)
IgE at 9 months (672)
At 6 years: IgE (460), lung function
(526), skin prick test (629)
Never wheezers: 51.5 %
Transient early wheezers: 19.9% (at least
one wheezing episode before 3 years, but
not afterwards)
Late-onset wheezers: 15% (wheezing
only after 3 yrs)
Persistent wheezers:13.7%  (wheezing
both before and after 3 years of age)
Transient wheeze associated with diminished lung
function in infancy
Persistent wheezing associated with elevated IgE
Maternal asthma associated with decreased lung
function at 6 years of age
Maternal smoking a risk factor for wheezing
Isle of Wight,
UK (21)
Recruitment 1989-
1990
1456 newborns, population
based
1034 attended all study
visits
Follow-ups at 1, 2 and 10 years,
questionnaires
Lung function (859) and AHR at 10 yr,
skin prick test, IgE
Never wheezers: 60%
Transient: 20%
Late-onset: 8%
Persistent: 12%
Persistent wheezing associated with atopy,
increased AHR and impaired lung function
MAS
Multiple cities,
Germany (16)
Recruitment 1990
1314 newborns, birth
cohort, 815 unselected and
499 high-risk, 939 followed
up to 7 years
Annual check-ups: interview, specific IgE
Lung function in 800 children at 7 years
Never wheezers: 65%
Transient: 25%
Late-onset: 5.3%
Persistent: 4.9%
Transient wheezers had normal/subnormal lung
function at 7 years of age
Persistent and late-onset wheezers had impaired
lung function at 7 years of age
ALSPAC
Avon, UK (18)
Recruitment 1991-92
14 541 newborns,
population based,
6265 followed up to 7 years
of age
Questionnaires at 7 time points from birth
to 7 years
Assessment of atopy, lung function, AHR
at 7-9 years
Never/infrequent wheezers: 59%
Transient early: 16%
Prolonged early: 9% (wheezing from age
6-54 months, low prevalence at 69
months and later)
Intermediate: 3% (onset 18 – 42 months)
Late-onset: 16%
Persistent: 7%
Atopy and AHR associated most strongly
associated with intermediate onset wheezing
Table 1. Preschool wheezing phenotypes in ten cohort studies.
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ECA
Oslo, Norway (20,32)
Recruitment 1992-93
3754 newborns, birth cohort
803 investigated at 10 years
Questionnaires every 6 months until 2
years of age, lung function at birth
(n=803), at 10 years (n=616) and 16 years
(550), skin prick test
Never wheezers: 69%
Transient: 9%
Late-onset: 9%
Persistent: 13%
At 10-16 years, 34% recurrent wheezers < 2 years
were free of asthma symptoms, medication or
increased AHR at 16 years. All symptomatics had
lower lung function than never wheezers.
BAMSE
Stockmann, Sweden
(23)
Recruitment 1994-96
4089 birth cohort,
population based
2965 at 4 years
2630 at 8 years
Questionnaires at 1, 2, 4, and 8 years,
physical and lung function examination at
4 (n=2965) and 8  (n=2630) years of  age
Never asthma: 84%
Transient: 9%
Late-onset: 3%
Persistent: 4%
More stringent criteria for asthma/wheezing than in
other cohorts
Transient and persistent symptoms associated with
reduced lung function at 8 years
MAAS
Manchester, UK
(17,29,30)
Recruitment 1995-97
1085 children, population
based
840 attended 5 year follow
up
Interview, lung function at 3, 5, 8 and 11
years
AHR at  5 years
Skin prick test
Never wheezers: 56%
Transient: 23%
Late-onset: 6%
Persistent: 15%
Poor lung function at age 3 predicted persistent
symptoms in children who had wheezed before the
age of 3
PIAMA
Multicenter,
Netherlands
(22,27,28)
Recruitment 1996-97
4146 newborns
1327 high risk (maternal
atopy)
2819 low risk
3164 follow-up at 8 years
Yearly questionnaires
Feno at 4 (1808) and 8 (1554) years,
spirometry at 8 years, total and specific
IgE, eosinophil count
Never/infrequent: 75%
Transient early: 16.7%
Intermediate-onset: 3.1%
Late-onset: 1.7%
Persistent: 3.5%
All wheezing phenotypes had a lower predicted
FEV1% predicted than did never-wheezers, with
the greatest deficit in persistent wheezers
COPSAC
Copenhagen,
Denmark (34,41)
Recruitment 1998-
2001
411 newborns with atopic
mothers
307 had all data available at
6 years
Troublesome lung symptoms assessed
daily, recorded at home
lung function in infancy (403) and at 7
years (317), skin prick tests,  IgE
No symptoms: 54%
Transient: 18%
Late-onset: 11%
Persistent: 17%
Children with asthma at age of 7 suffered lung
function deficit and increased AHR as
newborns(41)
Analysis based on troublesome lung symptoms
rather than wheezing
PASTURE
Austria, Finland,
France, Germany,
Switzerland (24)
Recruitment 2002-05
1133 birth cohort in rural
areas
953 complete data on
wheezing
Yearly questionnaires
Specific IgE
FeNO
Spirometry at 6 years
No/infrequent: 70%
Transient: 16.8%
Intermediate: 5.9%
Late-onset: 4%
Persistent wheeze 3.3%
International study
Used both latent class analysis and clinical
phenotyping
In utero smoke exposure was related to reduced
FEV1 in children with unremitting wheeze
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2.1.2 Bronchopulmonary dysplasia and lung function in early childhood
Improvements in perinatal care have substantially increased the survival of extremely
preterm infants (4). Bronchopulmonary dysplasia (BPD) usually affects infants born very
preterm and is characterized by dysregulated lung growth and prolonged oxygen
dependency (42). The definition of BPD is based on the need for supplemental oxygen for
at least 28 days after birth, and the severity of the disorder is graded according to need for
respiratory support at 36 postmenstrual weeks (4). BPD most often affects infants born
before 30 weeks of gestational age and weighing less than 1500 g at birth (4). Estimates
indicate that BPD devolopes in 12% to 32% of these infants (4,43) and may also affect
term infants with severe perinatal disorders (4).
Before the substantial advances in perinatal care the “old BPD” occured in slightly
preterm infants receiving aggressive mechanical ventilation and high concentrations of
supplemental oxygen (44). More effective methods of prevention with antenatal
corticosteroids, surfactant replacement after birth and a more conservative approach to
respiratory  care  have  reducted  the  prevalence  of  this  old  BPD  (4).  However,  higher
survival rates for infants with earlier gestational ages have meant that the overall
prevalence of BPD remains unchanged. These very premature infants are born before the
alveolarization has begun (4). The loss of normal structures of the lung now characterize a
“new  BPD”  pattern:  the  development  of  fewer,  larger  alveoli  with  dysmorphic
vasculature, which reduce the overall surface for gas exchange (43,45).
Wheezing in infants born prematurely is markedly higher than in children born at term
(4). Hospital readmission rates due to respiratory infections are high in children born
before the gestational age of 29 weeks (approximately half of the infants in their first year
of life) (46).  The infants with BPD are the most vulnerable and suffer from more severe
symptoms during the respiratory infections (4). Several studies have revealed that children
who were born preterm experience more wheezing and chronic coughing at the preschool
and school age, especially those with a history of BPD (47,48). Asthma-like symptoms
and the use of inhaled corticosteroids are significantly more prevalent among young
children born prematurely than among those born at term (49-52).
Weaning from supplemental oxygen in BPD children usually occurs before 2 years of
age (43), presumably due to postnatal alveolar growth during the first two years of life
(53). Studies have found that children and adults with a history of BPD show abnormal
diffusion capasity and impaired small airway expiratory flow (54,55). A Finnish study
examined 34 very low birth weight children at seven to eight years of age (56). One third
of these children experienced respiratory symptoms during the exercise or in contact with
cold air. They had lower forced expiratory volume in one second (FEV1), higher airway
resistance and higher rates of airway hyperreactivity than did term children (56). An
earlier Finnish study showed that children born very preterm exhibited increased bronchial
hyperresponsiveness, bronchial obstruction and bronchial lability at school age (57). A
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recent study from Norway found lower FEV1 values in children born at a gestational age ?
28  weeks  or  with  a  birth  weight ? 1000 g than in term-born controls (58); their lung
functions were assessed at the ages of 10, 18 and 25 years. Researchers used methacholine
and adenosine 5’-monophosphate (AMP) challenge tests with a modified auscultation
technique to evaluate preschool-age BPD survivors and asthmatics. This study found that
89% of children with a BPD history responded positively to methacholine, but only 21%
responded positively to AMP. All asthmatics responded positively to methacholine and
92% had a positive AMP result (59). A recent report also raised concerns about reduced
exercise capacity in persons born very preterm (43).
Despite substantial advances in perinatal care for premature births, the BPD survivors
continue to experience increased respiratory morbidity until adulthood. Although the long
term  effects  of  the  BPD  remain  unknown,  persons  who  have  suffered  from  BPD  in  the
neonatal period may be at great risk for developing the COPD phenotype as they age (43).
2.2 Risk factors for childhood asthma
The prelavence of asthma has risen in recent decades in industrialized countries (15).
According to surveys based on questionnaire data, asthma affects 5% to 16% of people
worldwide (15). Knowledge of the risk factors associated with asthma has advanced
considerable in recent years, mainly due to large cohort studies focused on this issue.
Heredity is widely considered important in asthma, but the rapid change in the prevalence
of asthma cannot result purely from genetic changes. Environmental and infectious factors
are known to be relevant risk factors for childhood asthma. Genome-wide association
studies (GWAS) have studied thousands of asthma cases and controls to identify
associations between genes and the disease (15,60).
For most asthmatics, asthma symptoms present early in life during their preschool
years. The strongest predictor for severe disease and persistent symptoms seems to be a
persistent bronchial obstruction (61,62). In mild asthmatics the lung function is not
substantially different from that of subjects without asthma; more severe asthmatics,
however, seem to show deterioration in lung function already in infancy, though the most
significant loss of lung capacity is thought to occur during the preschool years (15). The
preschool years therefore constitute an important period of life, when it may be possible to
influence the outcome of asthma later in life by modulating the risk factors and making
accurate diagnoses and treatment decisions.
2.2.1 Family history / genetics
A Finnish twin study in the 1990s investigated the heredity of asthma and atopic
diseases (63) by mailing a questionnaire to 2483 twin families. At the time of the study,
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the twins were 16 years old. According to this report, families in which at least one of the
parents had asthma, hereditary factors explained as much as 87% of their susceptibility to
asthma (63). The cumulative incidence of asthma in twins with asthmatic parents was
four-fold the incidence of twins without parental asthma.
In a Spanish population study of 2646 individuals, the risk for asthma in young
adulthood was 4.5 times higher in subjects with parental asthma than in subjects without
parental asthma (64). In a birth cohort from New Zealand, 18-year-olds with parental
asthma or hay fever had a 1.5-fold higher incidence of asthma than did subjects with no
parental asthma or hay fever (65).
Genome-wide association studies (GWAS) have reported several asthma-related gene
loci in at least chromosomes 1, 2, 5, 6, 9, 15, 17 and 22 (15). In most cases, other studies
have failed to replicate the genes reported in one GWAS with the exception of the 17q12-
21 gene (encoding ORMDL3-GSDMB), which appears to be associated with childhood
asthma but not with adult asthma (15,66). The PASTURE birth cohort study, which also
included Finnish children, found an association between the persistent wheezing and the
locus 17q21 (24). Nevertheless, associations of these loci with asthma are weak and
probably account for only a small part of the disease’s heritability. Multiple genes seem to
affect the pathogenesis of asthma, but the current genetic knowledge offers little
prognostic utility (15).
2.2.2 Infections
Viral infections are the most important causes of preschool wheezing. Bronchiolitis
refers  to  a  lower  respiratory  tract  infection  with  bronchus  obstruction,  edema,  cellular
debris and mucus, and resulting symptoms of wheezing(67). Based on the population
studies, the prevalence of bronciolitis is 18-32% in the first, 9-17% in the second, and 4-
12% in the third year of life (68,69). The need for hospital admission with bronchiolitis
among all infants under one year of age is 2-3% (70). The major viruses that cause
wheezing are respiratory syncytial virus (RSV), human rhinovirus (HRV), human
metapneumovirus and influenza viruses (71). A recent multicenter study of 2207 children
under two years of age with hospitalization due to bronchiolitis, found RSV in 72%, HRV
in 25.6%, other viruses or bacteria in 7.8% and multiple pathogens in 29.8% of children
(72).
RSV is the most common cause of viral bronchiolitis in infants during the epidemic
winter months, particularly in the first six months of life (72). The histopathological
findings in cases of fatal RSV bronchiolitis have revealed extensive airway epithelium
damage and small airway obstruction (73). A Swedish study followed 46 subjects who
required hospitalization due to RSV bronchiolitis in their first year of life up to the age of
18 years (74). They found a higher prevalence of asthma or recurrent wheezing (39% vs
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9%), sensitization to perennial allergens (41% vs 14%) and clinical allergy (43% vs 17%)
in children with a history of RSV than in control subjects at the age of 18 (74). Lung
function, as measured with spirometry, was reduced in individuals with past RSV
bronchiolitis. Another Swedish study found a ten-fold higher risk for adult asthma after
severe early wheezing over that of age-matched control subjects (75). Earlier reports have
shown a higher prevalence of asthma and allergic sensitization at the ages of 3, 7 and 13
years after brochiolitis (76-78). However, the Tucson birth cohort found RSV bronchiolitis
to be a significant risk factor for wheezing up to 11 years of age, but not at the age of 13
years (68). The severity of RSV bronchiolitis seems to be the strongest determinant of the
future asthma risk related to RSV in infancy (79). The question of whether RSV
bronchiolitis is a causal or genetic predisposing factor for asthma remains unanswered.
Some have argued that atopic diseases and viral infections may interact in multiple ways
to promote asthma in childhood. A genetic association study of RSV bronchiolitis in
infancy found that the haplotype at the IL13-1L4 locus raises the risk for severe primary
RSV bronchiolitis in infancy (80). This haplotype is associated with increased IL-13
production and atopic sensitization (80).
Human rhinovirus (HRV) is the second most common cause of wheezing disorders
during  the  first  half  year  of  life  and  becomes  the  most  common  pathogen  after  the  first
birthday (81). After the development of PCR techniques, some have recognized that HRV
causes not only common colds, but also lower respiratory tract infections (71). Reseachers
have identified at least 100 HRV serotypes and classified them into three groups (A, B, C)
(82). Rhinovirus bronchiolitis in infancy and asthma later in childhood are strongly
associated (83,84). A prospective follow-up study of 259 children with wheezy
bronchiolitis before three years of age found a ten-fold increase in asthma risk in children
with wheezy HRV and a 2.6-times higher asthma risk in children with RSV at the age of
six (84).
The mechanisms by which HRV increases the risk for asthma remains unclear, but
immunological factors are suggested to play a role. Researchers have proposed that HRV
damages the airway epithelium and consequently causes asthma (85). Another theory
postulates that some children are genetically predisposed to wheezing. In these individuals
HRV may act synergistically in a process, which leads to asthma (85). Low interferon
responses and atopy have been associated with HRV bronchiolitis (86). A low interferon-
gamma (INF-?) level in cord blood has proved to be a risk factor for wheezing illnesses
(87), and is also associated with atopy in childhood (71,88). Others have also suggested
that a minor group of wheezy infants have aeroallergen sensitization, which predisposes
them to severe wheezing during HRV infection (88). In addition, experimental studies on
HRV infections have shown increased pro-inflammatory mediator production in the
bronchial epithelium (89). Interestingly, reduced Th1 and increased Th2 cytokine
production have been reported during a HRV infection (90).
 The current understanding is that viruses other than RSV and HRV play only a minor
role in the pathogenesis of early wheezing and later asthma. Viral bronchiolitis in early
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life seems to be a major risk factor for wheezing and asthma in later life. A recent Finnish
study showed that asthma was currently present in 20% of subjects with bronchiolitis in
infancy, whereas the prevalence in controls at the age of 27 years was 5% (91). Whether
the viral bronchiolitis in infancy is a causal factor or a reflection of a predisposition
remains unclear.
2.2.3 Environmental factors
The main origin of the air pollutants is the combustion of fossil fuels (92). In urban
areas, a major source of air pollution is transportation-related emission. Chronic exposure
to diesel exhaust particles in childhood has been associated with increased risk for
persistent wheezing and asthma (93). Several studies have found associations between the
traffic pollution and childhood respiratory symptoms and sensitization to allergens (92).
The mechanisms, for how air pollutants cause asthma or airway inflammation, are not
fully understood, but evidence suggests that oxidative stress, the induction of persistent
inflammation and epigenetic mechanisms are involved in the pathogenesis (92). Others
have also suggested that exposure to indoor moulds is positively associated with the
asthma incidence in children (94). The proposed mechanisms may not be associated with
allergies, but the induction of inflammation due to fungal chitin may play an important
role (95).
Several published reports have explored the effects of living on a farm in childhood on
the  development  of  atopic  diseases.  The  original  hygiene  hypothesis  refers  to  the
assumption that unhygienic conditions, large families and overcrowding reduce the
incidence of atopic diseases and asthma (96). Exposure to microbial diversity reportedly
suppresses Th2 immunity, but this may be an oversimplification (96). Nevertheless,
studies repeatedly show that living on a farm in early childhood or while in utero protects
against asthma and atopy (97,98). A Finnish birth cohort study of 410 children showed
that the quantity of microbial exposure in early childhood predicted asthma at the age of
six years (99). Those at highest risk for asthma had a median level of microbial exposure
(99).
Interestingly, the large multicenter study CABRIEL, found that children living on
farms are protected from wheezing independently of atopy (100). The study analyzed
8023 children stratified according farming exposure. The prevalence of current wheezing
among nonatopic children exposed to a farm environment was lower than in nonexposed
children (100). This finding supports the concept that an imbalance of Th1/Th2 immunity
does not exclusively explain the hygiene hypothesis (96). Research suggests that a farm
environment may influence airway inflammation through antiviral properties and alter the
microbiome of the airways (100).
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2.2.3.1 Environmental tobacco smoke
Exposure to tobacco smoke products is a global health risk factor, especially for
respiratory health, but also lung cancer, cardiac disease, chronic obstructive lung disease,
sudden infant death syndrome, middle ear infections and asthma (101). Estimated
worldwide mortality due to smoking is 5.7 million people annually (102). Nor are the
harmful effects of smoking restricted to the active smoker. Exposure to environmental
tobacco smoke (ETS) influences the unborn baby and child living with smoking parents.
Research has suggested that the exposure level of a fetus of a smoking pregnant woman is
20 times higher than exposure level in ETS (103). Finnish legislation has diminished
exposures to ETS in public and working places since 1985 (104), but a child can still be
exposed to ETS at home. However, studies have shown smoke-free legislation to be to be
associated with reduced pre-term births and hospital attendances for asthma (102).
According to the latest national statistics, 21% of Finnish men and 14% of Finnish
women smoked in 2012 (105). The same statistics show that 16.6% of the pregnant
women smoke.  Children  can  be  exposed  to  tobacco  smoke  not  only  at  home but  also  in
public places. ETS contains thousands of harmful chemicals, including both nitric oxide
and superoxide (106), and consists of sidestream smoke from burning cigarettes and
exhaled  mainstream smoke (11).  At  least  50  ETS chemicals  are  known to  cause  cancer,
heart diseases and respiratory illnesses such as asthma and COPD (11). Because
sidestream smoke is produced at a lower temperature and under more reducing conditions
than mainstream smoke, many toxicants are generated in higher concentrations in
sidestream smoke than in mainstream smoke (107). Moreover, many chemicals are present
in different phases in various constituents; nicotine, for example, is present in the
particulate phase in mainstream smoke and in the vapour phase in sidestream smoke (11).
Particle sizes in sidestream smoke are smaller than in mainstream smoke, and are
therefore more easily penetrated deeper into the lungs and smaller airways of children
(11).
Studies have shown that exposure to maternal prenatal smoking reduces newborn lung
function. Some studies have measured lung function several weeks after birth, making it
difficult to distinguish the effects of pre- and postnatal ETS (101). A Norwegian study
which assessed the lung function of infants with smoking mothers on their second to fifth
day of life showed a dose-response association between reduced lung function and
exposure to tobacco smoke (108). British (109) and Australian (110) studies have reported
similar findings and even in prematurely born infants with smoking mothers (111).
Swedish researchers showed that pre- and postnatal ETS increased the risk for asthma in
early adulthood (112). They also found that a connection between in utero smoke
exposure and asthma appears to be mediated via the development of airway
hyperresponsiveness. Furthermore, smoke exposure in infancy increased smoking in
adulthood, which is linked to adult asthma (112).
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Knowledge of the exact mechanisms for how ETS reduces lung function in newborns
is lacking. The placenta offers no protection against nicotine or other pollutants (11).
Nicotine affects placental function by inducing epinephrine release into the maternal blood
and thereby reduces circulation in placenta (11). Consequently, some researchers have
speculated that the smoking during pregnancy generally inhibits growth leading to smaller
infants and lungs (101). However, several studies also show consistent findings of reduced
lung compliance in infants, suggesting structural changes in the lungs (113). Studies have
also found a significant increase in thickness of the inner airway wall in children with
sudden infant death and those exposed to tobacco smoke (114). Another study of fetal
tobacco smoke exposure found fewer and larger saccules in exposed rats than in non-
exposed rats (115). Evidence suggests the involvement of pulmonary neuroendocrine cells
(PNEC) in lung defects caused by ETS. PNECs are present in large numbers during the
fetal period, but decrease rapidly during the first year of life (101). Several respiratory
conditions, such as asthma, sudden infant death and BPD, are associated with high
numbers of PNECs (116). Animal models have shown an association between altered
fibrillar collagen expression and nicotine receptors in lungs (117).
ETS  and  an  increased  prevalence  of  asthma  are  associated  (11).  In  a  Finnish  cohort
study of 60 000 children found a dose-response fashion with maternal smoking during
pregnancy and asthma in seven year old children was found: if a mother smoked < 10
cigarettes/day the risk for asthma was 1.2 fold; for > 10 cigarettes, it was 1.4-fold (118).
Exposure to tobacco smoke is also associated with wheezing, upper and lower respiratory
tract infections, otitis media and coughing in childhood (11). Recent reviews and meta-
analyses revealed an association between the maternal smoking and higher risk for both
wheezing and asthma. A meta-analysis of 79 prospective studies found a 30-70% higher
risk for childhood wheezing and 21-85% for asthma if a mother smoked (119).
Distinguishing between pre- and postnatal exposure is difficult, but studies suggest that
postnatal  maternal  smoking  raises  the  risk  for  wheezing  in  children  two years  of  age  or
younger (119). Another recently published meta-analysis reported that postnatal maternal
smoking was associated with a 1.2-fold higher risk for wheezing in children under six
years old (120).
ETS also influences lung function, the deterioration of which is not restricted only to
asthmatic children exposed to ETS, although the negative effect on lung function seems to
be greater in asthmatics (121). A meta-analysis of childhood lung function in relation to
ETS found that 18 of the 21 studies examined identified a relationship between a
reduction in FEV1 and ETS (122). The authors concluded that maternal smoking is
associated with a small but yet significant deterioration in lung function at school age but
most of the effects appears to stem from maternal smoking during pregnancy (122). A
large, international cohort study found that prenatal ETS reduced mean expiratory flow at
25% of vital capacity (MEF25) by 6% and forced expiratory volume in one second (FEV1)
by 1%. The association with current ETS was lower, but still significant: -0.5% for FEV1
and -2% for MEF50 (123). Cultural differences may explain contradictory findings in
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studies from Turkey (124) and China (125), where the reduced lung function in children
was associated with paternal smoking.
A growing body of data indicate that exposure to tobacco smoke affects the immune
system and may interact with genes in epigenetic or epistatic ways. Some researchers have
postulated that tobacco smoke enhances Th2 immunity, induces oxidative stress and alters
the histone acetylase balance (126). A murine model reported exaggerated
immunoglobulin E (IgE), immunoglobulin G1 (IgG1), eosinophil, interleukine 4 (IL4) and
IL-10 productions in the presence of ETS in sensitized mice (127). One study of asthmatic
school-age children found an association between ETS and leukotriene E4 in urine (128).
Another study reported an interaction between a CHRNA3/5 polymorphism and ETS for
bronchial hyperresponsiveness in children. The locus of this gene encodes the subunits of
the acetylcholine reseptor, which mediates airway cholinenergic activity (129). Studies
have shown that the locus of gene 17q21, which is associated with childhood asthma,
affects the development of asthma more strongly if the mother is smoking (130).
Cotinine and ETS
Most of the studies that have investigated children’s exposure to parental tobacco
smoke are based on questonnaires in which parents report their smoking habits. Because
people often underestimate their bad habbits, this method may produce biased results. A
more realiable method to monitor exposure to second-hand smoke is to measure the
cotinine level in body fluids and hair (131). Cotinine is a major nicotine metabolite and
can be measured in serum, urine, hair or saliva (131). Most of the nicotine metabolism
occurs in liver, which metabolizes 70-80% of nicotine to cotinine (132). Cotinine is more
stable and has a longer half-time (20-30 h) than nicotine (2 h) (131). Cotinine
measurements in body fluids are estimated to reflect exposure to tobacco smoke in
previous three to four days (12). Studies have found a positive association with children’s
urinary cotinine and parental smoking and in particular maternal smoking seems associate
strongly with children’s exposure (131,133,134). Some reports have shown an association
between children’s urinary cotinine levels and reduced lung function (133,135,136). Some
individual variability in nicotine metabolism due to gene polymorphism in CYP2A6 may
influence interpretation of the cotinine results (131). Urinary cotinine can be measured
with chromatographic techniques, radioimmunoassays (RIA) or enzyme-linked
immunosorbent  assays  (ELISA)  (137).  The  lower  detection  limit  of  the  methods  is  as
follows: chromatographic techniques 0.1-1.0 ?g/l, RIA 0.1-2.0 ?g/l and ELISA 0.1-0.2
?g/l(137). The recommended cut-off value for urinary cotinine from exposure to tobacco
smoke is 0.5 ?g/l (131,137). Few studies have investigated the association between
children’s cotinine levels and FeNO or lung functions indices. Table 2 summarizes these
studies.
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Table 2. Studies reporting cotinine levels in relation to FeNO or lung function in asthmatic
children.
Study Subjects, n (age) Cotinine level Associations with cotinine
Chilmonczyk et al
1993(133)
199 (4-10 years)
asthmatics (145
with lung
function)
5.6 ng/ml (urine) in non-
exposed
23.3 ng/ml in exposed
Reduced FEV1, FEF25-
75% and FEV1/FVC
Increased number of
exacerbations
Oddozze et al
1999 (134)
90 (4-14 years)
asthmatics
Urinary cotinine:
No ETS: median 0.0 ?g/l
Mother only: 20 ?g/l
Father only: 3.5 ?g/l
Both: 7.5 ?g/l
No association with
baseline spirometry
Association with AHR to
carbachol
Spanier et al
2006(138)
170 (6-12 years)
asthmatics
All exposed
2.2 ? 8.8 ng/ml (serum)
No association with FeNO
De la Riva-
Velasco et al
2012 (139)
33 (8-18 years)
asthmatics
urinary cotinine
? 1ng/ml (n = 10)
< 1ng7ml (n = 23)
Poorer asthma control
Lower FeNO level
Leung et al
2013 (136)
2763 (mean age
4.5 years)
general
population
High cotinine-to-
creatinine ratio (? 30
ng/mg) in 10.6% and
measurable in 62.4% of
children with cotinine
assessments (n = 893)
High urinary cotinine and
lower FEV0.5, FEF25-75 and
PEF associated
Hernández-
Alvirez et al
2013(128)
49 asthmatics
41 controls
5-13 years
Urinary cotinine:
Asthmatics 1.98,
non-asthmatics 1.23
ng/mg creatinine
Urinary cotinine and FEV1
and FVC inversely
correlated
Howrylak et al
2014 (140)
619 (1-16 years)
asthmatics
56.1% had detectable
cotinine in serum and
79.6 % in saliva
Detectable cotinine levels in
serum and saliva were
associated with readmission
to hospital within a year
Gill et al
2014 (141)
40 (8-18 years)
asthmatics
70 % urinary cotinine ?
1ng/ml
30 % < 1ng/ml
No association with FeNO
or FEV1
Higher urinary LTE4 in
ETS exposed with ICS, but
not with montelukast
Valsamis et al
2014(135)
41 preschool
asthmatics
15 had > 1ng/ml FEV1 decreased in children
with > 5ng/ml cotinine, no
effect on IOS indices
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2.3 Diagnosing asthma in preschool children
Asthma is defined as a chronic disorder with airway inflammation and
hyperresponsiveness, which lead to recurrent episodes of obstructive respiratory
symptoms (wheezing, coughing, dyspnea or chest tightness). Taking into account the
heterogeneous features of preschool wheezing or asthma-like symptoms and the difficulty
in measuring objective lung function in this age group, no simple and clear definition for
asthma in preschoolers exists.
Several  guidelines  for  the  diagnostics  issues  associated  with  preschool  asthma  are
available (13,142,143). Current international guidelines recommend taking a history of
recurrent respiratory symptoms as a key method for diagnosing asthma in children (13)
(Table 3). Wheezing, coughing, dyspnea, and chest tightness are typical of asthma and the
symptoms are often worse at night or early in the morning. Exposure to various stimuli
such as cold, exercise, tobacco smoke, allergens, respiratory infections, laughter or crying
may trigger episodes of respiratory symptoms (13). The guidelines do not specify the
number of symptomatic episodes needed for a diagnosis of asthma in preschool children
but do recommend an arbitrary number of three or more. A personal history of atopy
(allergic rhinitis, eczema, food/aeroallergen sensitization) as well as a family history of
asthma strengthens the diagnosis (13). Physical examination should include chest
inspectation and auscultation for wheezing or any other abnormalities in breathing sounds.
A chest X-ray is recommended for a differential diagnosis, and a positive outcome in
therapeutic trial may also support a diagnosis of asthma. Because symptoms of asthma
may stem from various conditions, a differential diagnosis is crucial. A list of important
differential diagnoses appears in Table 4.
An Asthma Predictive Index (API) was developed based on the Tucson cohort to help
in assessing the risk for persistent asthma in children younger than three years of age
(144). The API is based on both major (parental asthma and atopic eczema) and minor
criteria (allergic rhinitis, wheezing without colds, eosinophilia) (145). A positive API
score is defined as having recurrent wheezing episodes before the age of three (< 3 / year
in loose and ? 3 in stringent index) and one of two major criteria or two of three minor
criteria (144). Several studies have sought to validate the use of API or to develop new
predictive indices (21,36,146-148). Positive likelihood ratio of API regarding the risk for
asthma ranges from 2.5 to 7.9 among 6- to 13-year-old children with early wheezing
(149). The negative likelihood ratio ranges from 0.53 to 0.91 (149). A modified API
includes three major criteria (parental asthma, atopic dermatitis and aeroallergen
positivity) and three minor criteria (allergic sensitization to milk, egg or peanuts,
wheezing unrelated to colds and eosinophilia) (150).
The evaluation of lung function is essential in both diagnosis and monitoring of asthma
control in school-age children and adults. In preschool-age children asthma diagnoses are
mostly based on clinical symptoms. The International Consensus on pediatric asthma
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(ICON) (13) recommends spirometry for children old enough to perform it properly
(proposed  range  of  minimum  age  is  5  to  7  years  of  age).   ICON  states  that  in  children
under five years of age, newer techniques such as oscillometry or spesific airway
resistance can be used. Finnish guidelines recommend the use of oscillometry from the
age of three years to assess lung function and to diagnose asthma (151). Normal lung
function in mild to moderate asthmatics does not exclude asthma (152). In such cases the
AHR  tests  may  offer  an  additional  aid  to  achieve  the  correct  diagnosis.  Given  the
heterogeneity of the asthmatic symptoms in young children, objective methods for the
assessment of lung function, airway inflammation and airway hyperresponsiveness are
needed to enhance proper asthma diagnoses and to avoid unnecessary medications.
Table 3. Diagnosis of preschool asthma (13,143)
History of respiratory symptoms
Recurrent obstructive respiratory symptoms (wheeze, cough, dyspnea, chest tightness)
Symptoms worse at night or in early morning
Exacerbations by exercise, viral infections, allergens, environmental factors
Personal history of atopy (eczema, food allergy, allergic rhinitis)
Family history of atopy or asthma
Physical examination
      Inspection of the chest
      Auscultation for wheezing
      Inspection of the skin for eczema
      Signs of rhinitis
Lung function (in Finland, oscillometry is recommended from the age of 3)
Evaluation of atopy (skin prick tests or specific IgE)
Chest X-ray for differential diagnosis
Therapeutic trial
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Table 4. Diffrential diagnosis for respiratory symptoms in small children (13,143)
2.4 Measuring lung function in young children
Lung function testing plays a key role in assessing of diagnosis and managing chronic
pulmonary conditions in school-age children and adults. However, the objective
measurement of pulmonary function in children under six years of age is uncommon,
mostly due to the cooperational challenges in this age group. Manoeuvers needed in
spirometry may be difficult for many preschoolers to perform. Consequently, significant
efforts have aimed to develop techniques that noninvasively measure lung function in
young children during tidal breathing.
A number of methods to measure preschool lung function have been introduced, many
of which have proved safe, feasible and easy for a young child to perform (153).
Spirometry has been suggested in preschoolers using the modified acceptability criteria,
but there is limited data regarding the intepretation of the bronchodilatation response,
usage with the exercise test and bronchoprovocative challenges in this age group
(154,155). However, the ATS/ERS statement provides reference values for baseline
spirometry values (153), and more recent publications present additional data (156,157).
For preschool children who may be unable to produce exhalation for one second,
researchers report the forced expiratory flow at 0.5 or 0.75 second (158).
Immunological and infectious disorders
Recurrent respiratory tract infections
Bronchiolitis
Allergic rhinitis and sinusitis
Anaphylaxis
Tuberculosis
Sarcoidosis
Immune deficiency
Pertussis
Mechanical obstructions
Congenital malformations
Foreign body aspiration
Laryngotracheamalacia
Tracheal stenosis, bronchostenosis
Enlarged lymph nodes or tumor
Vascular rings or laryngeal webs
Bronchial pathologies
Primary ciliary dyskinesia
Cystic fibrosis
Bronchiectasis
Bronchopulmonary dysplasia
Other systems
      Heart disease
Gastroesophageal reflux disease
Neuromuscular disorder
Psychogenic cough
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One can use a mouthpiece in a body pletysmograph to assess specific airway resistance
(sRaw) during the tidal breathing (159). Reports have shown sRaw to be higher in
asthmatic children than in healthy controls (160). sRaw can also serve to assess bronchial
hyperresponsiveness and the bronchodilator effect (161), but standardized guidelines for
sRaw are necessary (161).
The interrupter resistance (Rint) method offers a noninvasive and quick assessment of
respiratory resistance during tidal breathing. This method involves briefly occluding the
airway opening, and the ratio between resistance difference and airflow is the interrupter
resistance (Rint) (153,162). Rint has shown 70-92% specificity and 24-76% sensitivity in
distinguishing between children with current wheezing and healthy controls (161).
However, bronchoprovocative tests have revealed a large inter-individual distribution of
normal values and discrepancies between Rint and other pulmonary function tests (158).
The MBW (multiple breath inert gas washout) technique is based on the measurements
of gas distribution and mixing within the lungs (161). The method provides measurements
of lung volume and ventilation inhomogeneity during tidal breathing (161). MBW has
proved to be a good indicator of lung function deterioration in preschool wheezers (160).
However, clinically meaningful thresholds for the method are unavailable and the lack of
commercial equipment limits the use of this technique in everyday practice (161).
2.4.1 Impulse oscillometry
2.4.1.1 Technique
In 1956, DuBois first introduced the forced oscillation technique (FOT) (163). FOT is
a general impression for the airway mechanistical measurements, which utilize non-
invasive pressure fluctuations over the subject’s normal, tidal breathing. Impulse
oscillometry (IOS) is a modification of the FOT, which uses rectangular pulse signals
during the tidal breathing instead of sine-curved waves in FOT (5,164).
IOS delivers a large sample of different frequencies of pressure waves, which are
thought to provide a detailed characterization of the lung function (165). IOS can serve to
measure lung function in both adults and children (165,166). IOS uses a methodology
involving a loudspeaker that generates oscillation pressure waves. These regular square
waves are transmitted to the airway system, usually at the mouth (166). The pressure
oscillations act via movement of the air column in the airways and cause the elastic
components of respiratory tract tissues to distend and recoil and create backpressure (165).
Impedance (Zrs) is a term that refers to a pressure-flow relationship produced by the
oscillation technique (166). Impedance is composed of the resistance (Rrs) and reactance
(Xrs) of the respiratory system.
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Rrs describes the mechanical properties of the respiratory system and is calculated
from the pressure and airflow signals, where pressure is in phase with the flow (165). Rrs
measures both central and peripheral resistance from the oropharynx to the distal lungs
and the thoracic wall tissue (166). Reactance (Xrs) is related to the energy storage
capability of the airway system and is determined by its elastic properties (165). It is
calculated from the relationship of the pressure and volume (167). Elastic properties are
prominent at low frequencies and the inert properties become more relevant with
increasing oscillation frequencies. Resonance frequency (Fres) refers to the point at which
the transition from the passive distension to active stress in the lungs occurs (166).
The oscillations in IOS are applied in a fixed square wave frequency at 5 Hertz (Hz),
from which all other frequencies derive (165). Resistance and reactance at 5 Hz are termed
as R5 and X5, respectively. Low frequencies of 5 Hz or less are considered descriptive of
both peripheral and proximal lung mechanics and are thought to provide an overview of
the  lungs.  Instead,  high-frequency  oscillations  such  as  20  Hz  are  proposed  mainly  to
reflect the large airways function (165). The term frequency dependence refers to this
distinct  capability  of  low  and  high  frequency  oscillations  to  reflect  conditions  of  the
peripheral and proximal parts of the lungs (5,167). R5-R20 is calculated from the
difference between R5 and R20 and is proposed to be a measure of the peripheral airways
(168,169). The terms total resistance (R5), central resistance (R20), small airways
resistance (R5-R20), distal reactance (X5) and reactance area (AX) are conventionally
used in IOS measurements (166).
Coherence, a measure of the correlation between airflow and pressure, is an estimate
of the reliability of the IOS (165). Low coherence may reflect the inability of the patient to
relax, leakage from the mouthpiece, irregular breathing, improper bracing of the cheeks,
an inadequate seal with the nose clip, swallowing, vocalization, coughing, closing of the
glottis or closure of the airflow by the tongue (165). Three to five acceptable
measurements should be performed (153). The coefficient of variability (CV) is calculated
and serves as an indicator of trial-to-trial variability. Reports show that the CV in children
ranges from < 5 to 17% (167). This range suggests that achieving similar results in
consecutive measurements is easy (165). During the measurement, the sublect’s or
examiner’s hands must support the cheeks in order to compensate for the compliance of
the cheeks (5). A nose clip prevents the oscillations to escaping from the nares (5).
2.4.1.2 Clinical applications in young children
ATS/ETS  Statement  proposes  the  IOS  technique  as  one  of  the  techniques  for
measuring lung function in preschool children (153). The statement concludes that the
oscillometric technique is a promising method for diagnosing airway obstruction,
reversibility and hyperresponsiveness (153,165). Most reports have defined R5 as a
specific primary outcome variable in IOS measurements (158). The Finnish guidelines
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recommend measuring lung function with IOS in children from three years of age. Most
children under six years of age are incapable of performing maneuvers needed in
spirometry,  which  is  widely  used  in  school-aged  children  and  adults.  IOS  requires  only
passive cooperation and can be performed during quiet, tidal breathing (165,166). More
than 80% of young children are able to perform oscillometry successfully (5,158). Studies
have reported success rates of 40% in four-year-olds and 83% in 5-year-olds (166). In a
Finnish report 89% of two- to seven-year-olds were able to perform IOS successfully (5).
The normal reference values for children are based in their standing height (170),
which appears to be the strongest dependent factor. The children’s height and the R5 value
are inversely associated (5,171,172). The IOS reference values for Finnish preschool-age
children are provided based on a study of 109 healthy two- to seven-year-olds (5,173).
IOS can serve to determine lung function in both asthma and other lung disorders
(167,174,175). The clinical diagnostic capacity of respiratory impedance of IOS is
comparable to that of spirometry (167). In school-age children IOS has shown consistent
results with spirometry (176).
Children with stable chronic lung diseases often have normal baseline resistance
values (158). To determine positivity to a bronchodilator, researchers have suggested a
decrease of 15-40% from baseline IOS resistance, and recently proposed a cut-off value of
40% (158,177,178). In healthy Finnish children the mean percentage decrease in R5 after
inhalation of salbutamol was 19.2% (5). An American study examined 73 four-year-olds
and found that bronchodilator response with IOS discriminated between the children with
and without asthma (179). In a Finnish study of 96 preschool children, baseline R5 and
post-bronchodilatation R5 were able to distinguish between the wheezy and healthy
children (180).
No established cut-off values have been published for the bronchoprovocation tests
using IOS. However, studies have shown an association between the asthma symptoms
and positivity in the methacholine challenge with IOS in adult asthmatics (181). The
exercise test with IOS can succesfully distinguish between the pediatric asthmatics and
controls (182). IOS (increase in R5) and spirometry (decrease in FEV1) showed agreement
in  the  exercise  test  in  young  adults  (183).  The  bronchoprovocative  tests  with  IOS  are
addressed in more detailed later in this thesis.
The  main  limitation  of  the  IOS  technique  is  that  it  fails  to  differentiate  between  the
obstructive and restrictive conditions (167). The technique is also sensitive to the artifacts,
which should be carefully monitored during the measurement (167). Upper airway
artifacts can be controlled for holding the cheeks during the measurement, and by
avoiding movements during the performance (166,167). The strength of the IOS technique
is its need of minimal cooperation, which is why it is recommended when cooperation
difficulties preclude the use of spirometry (167).
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2.4.2 Airway hyperresponsiveness assessment
Airway hyperresponsiveness (AHR) is one of the key features in asthma. AHR refers
to an abnormal increase in airflow limitation following various natural or pharmacological
stimuli (184). The first reports of the bronchoprovocative tests are by Tiffeneau in the
1940s (6). Bronchial challenge tests can serve to assess AHR in patients with symptoms
and signs suggesting asthma. A large number of provocating agents have been developed
since the first reports of AHR (185). These agonists are divided into direct and indirect
agents to emphasize the heterogeneity of the reactions resulting from various stimuli
(186,187). An overview of such direct and indirect stimuli appears in Table 5.
Direct stimuli act directly on airway smooth muscle cell reseptors, and indirect stimuli
cause airway constriction through mediators. A schematic illustration of the mechanisms
of direct and indirect bronchoconstrictive stimuli appear in Figure 1.
Two semi-independent components of AHR have been identified; variable and fixed
components (188,189). The variable component is transient and inducible, and may be
result of, for example, allergens. It improves rapidly with medication or environmental
control (188) and is associated with airway inflammation, current asthma activity and
exposures (188). The fixed component is relatively persistent AHR, which occurs in many
but not in all chronic asthmatics. This phenomenon is also called airway remodelling,
which refers to the structural changes that take plase in the airway walls (189).
Table 5. Direct and indirect challenge tests.
Direct stimuli Indirect stimuli
Methacholine Exercise
Histamine Eucapnic voluntory hyperpnea
Asetylcholine Hypertonic saline
Carbachol Mannitol
Prostaglandin D2 Adenosine
Leukotriene C4/D4/E4 Metabisulfite
Sulfur dioxide
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Figure 1. Schematic illustration of the mechanisms of direct and indirect bronchial stimuli.
2.4.2.1 Direct challenges
Direct bronchoprovocative tests acts directly on the airway smooth muscles to cause
airway contraction.  The  most  widely  used  direct  tests  for  clinical  and  research  purposes
are methacholine and histamine challenges (190). Histamine acts on histamine (H1)
receptors and methacholine in muscarinic (M3) receptors on the bronchial airway smooth
muscle cells (Figure 2). These activations cause the cells to depolarize and contract,
thereby constricting the bronchi (191). Direct hyperresponsiveness is only weakly related
to  airway  inflammation  of  the  airways  (192),  but  attenuates  after  the  use  of  inhaled
corticosteroid. Direct tests most often serve to rule out asthma, since they have high
sensitivity, but low specificity (6). The list of direct AHR tests appears in Table 5, with the
most frequently used tests appearing in bold.
Methacholine challenge
Methacholine chloride (acetyl-?-methacholine) is a parasympathomimetic analog of
acetylcholine, and causes bronchial smooth muscle constriction by stimulating the
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muscarinic, parasympathetic receptor (193). American Thoracic Society recommends two
alternative protocols for the methacholine challenge: 1) the 2-min tidal breathing method
and 2) the five-breath dosimeter method (194). The dosimeter method may have a lower
sensitivity especially in mild asthmatics, because it includes deep breaths, which are
considered to be bronchoprotective and bronchodilative (189). In addition, the delivered
dose is lower in the dosimeter method than in the tidal breathing method (189).
A 20% fall in forced expiratory flow (FEV1) is considered as a positive test result. The
dose of the agonist (PD20FEV1) needed to cause this fall is calculated by interpolation
from the dose response curve (190). Methacholine is considered to have a high sensitivity
to current asthma but low specificity (6). Patients with allergic rhinitis, atopy, and other
lung diseases, as well as patients who smoke may have AHR to methacholine (190).
Therefore, the methacholine test often serves to rule out current asthma (6).
Studies have shown some genetic linkages between the direct AHR and asthma-
associated genes (184). Association studies between the inflammatory markers and direct
AHR have shown somewhat contradictory results (195). The number of mast cells and
eosinophils has shown a weak association with AHR (184,196). Patchy desquamation of
the epithelium, airway smooth muscle hyperplasia and hypertrophy as well as vascular
hyperplasia may explain part of the AHR in asthmatics (184). Therefore, it is postulated
that the direct AHR in asthmatics results from both inflammatory and structural changes in
the airways (184).
Only few studies have examined the methacholine provocation test and other AHR
tests in preschool-age children, mostly due to the challenges in measuring the lung
function in this age group. Many of the children under six years of age are incapable of
performing the manoeuvers needed in spirometry. They can, however, perform the
impulse oscillometry, which demands minimal cooperation. Table 6 summarizes studies
that have used AHR tests to distinguish various pediatric patient groups in children and
studies that have examined AHR in preschoolers.
In the 1990’s investigators used methacholine, adesonine and exercise challenges with
spirometry to study a group of 6- to 25-year-olds. The investigators reported that
methacholine distinguished children with asthma and pediatric COPD from controls, but
not asthma and COPD patients from each others (197). Exercise and adenosine did
differentiate asthmatics and COPD children from controls and from each other (197). A
study of five- to six-year-old wheezy children found that neither the methacholine nor
hypertonic saline tests with IOS successfully distinguished between the past and present
wheeze or the degree of the clinical severity of the symptoms (198). A subsequent study
reported higher adenosine, but not methacholine responsiveness in preschool age children
with atopic asthma than in children with non-atopic asthma (199). AHR was assessed with
a modified auscultation method.
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A Danish study examined sRaw, Rint, IOS and the transcutaneous measurement of
oxygen with methacholine challenge in two- to four-year-olds  (200). They found that IOS
was suitable for young children for measuring AHR. The most sensitive of these tests was
sRaw, the second most sensitive was Xrs5 with IOS. IOS reportedly detected 70-80% of
five-year-olds who responded to the methacholine test with spirometry (201).
Large cohort studies have used methacholine challenge test results as a sign of a
childhood AHR and a possible trajectory for later asthma. A Danish study found an
association  of  neonatal  AHR  to  methacholine  and  asthma  at  seven  years  of  age  (41).  A
Norwegian report  showed that AHR to methacholine at  the age of ten years was a more
accurate predictor than the exercise test for asthma six years later (202). A report from the
Tucson cohort found that AHR to methacholine at the age of seven was associated with
persistent wheezing and atopic markers in early life (25).
The exact role of the methacholine test in diagnosing childhood asthma remains
unclear. Canadian researchers studied 215 children with doctor-diagnosed asthma and 197
healthy controls with methacholine challenge test (203). They found in these seven- to
nine-year-old children that methacholine had a positive likelihood ratio of 2 for doctor-
diagnosed asthma in atopic girls and 2.6 in atopic boys. In nonatopic children the
methacholine test offered no help in diagnosing asthma (203).
2.4.2.2 Indirect challenges
Indirect challenges cause the airways to narrow by releasing endogenous mediators,
which cause the airway smooth muscles to contract (7). Inhaled corticosteroids deteriorate
or complete inhibit responses to indirect challenges, and these test are thought to reflect
more  closely  airway  inflammation  than  direct  challenges  (186).  Indirect  tests  are
considered to be highly specific but less sensitive for asthma (7). Most natural stimuli that
provoke asthmatic attacks, such as exercise of allergens, in everyday life act indirectly (7).
The list of indirect challenges appears in Table 1. Challenges that are commonly available
in pulmonary laboratories appear in bold.
Exercise test
Exercise induced bronchoconstriction (EIB) is defined as an acute airway narrowing
that results from vigorous exercise (204). The first reports of the exercise test in children
were published in the 1960’s (205-207). The exercise test is the first standardized indirect
challenge test in children (208). Exercise is a natural way to induce airway symptoms in
asthmatic children (209), and estimates indicate that 40–90% of asthmatics experience
respiratory symptoms during exercise (210,211). EIB has been found also in subjects with
no known diagnosis of asthma (204).
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EIB results from changes in lung function evoked by exercise, and the FEV1 is the
recommended lung function measure to assess EIB (204) in school-age children and
adults. Symptoms of EIB are nonspecific and variable and have poor predictive value for
objectively confirmed EIB (212,213). The severity of EIB can be graded by the magnitude
of change in lung function in the exercise test. According to the American Thoracic
Society (ATS) guidelines, a 10-25% drop in FEV1 from the pre-exercise level is
considered mild EIB, a 25-50% drop indicates moderate EIB and a ? 50 % drop indicates
severe EIB (204).
Two competing hypotheses describe the mechanism of EIB. The first is based on the
heat loss and the subsequent vascular engorgement that ensues as the airways rewarm after
exercise and initiate the constriction of the airways (214). This theory is unrelated to
mediator release. The second proposed mechanism is grounded on the water loss from the
airways during exercise as the lower airways must condition large volumes of air in a
short time (210). This leads to a change in osmolarity, which is thought to activate mast
cells, sensory nerves and epithelial cells and to release inflammatory mediators, such as
leukotriens, prostaglandins and histamine, thereby constricting the bronchi (210,215).
The osmotic mechanism of EIB is the most accepted theory today. Investigation of 25
asthmatics with EIB found the realease of epithelial cells, mast cell mediators and
eicosanoids into the airways during EIB (216). The eosinophil count in induced sputum
and the severity of EIB shows a correlation (217). Sensory airway nerves may also be
involved in mediator release into airways during EIB by releasing neurokinins, which
cause airway constriction and mucous secretion (218).
The exercise test with IOS can serve to identify EIB in young children who are
incapable of performing spirometry. A 35-40% increase in resistance at 5 Hz (R5) after
exercise is considered as EIB (153,167,182). A study of three- to seven-year-old wheezy
children and non-atopic controls revealed that wheezy children showed significantly larger
responses in IOS indices than did nonatopic controls (182). The exercise test was
performed as a free running test. Physical activity is natural for a child, so the exercise test
is a good way to induce symptoms of asthma in children. IOS and spirometry parameters
after the exercise test have correlated well in young adult asthmatics (183).
The exercise test defies standardization, in that controlling exercise intensity and
environmental factors is challenging. This difficulty has lead to the search for surrogate
tests, such as the eucapnic voluntary hyperpnea (EVH) challenge, and the hypertonic
saline and mannitol tests (210). Direct challenges act directly on smooth muscle receptors
and depend less on airway inflammation (219), so any association with indirect challenge
tests is only modest (186).
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Mannitol challenge test
Mannitol is a sugar alcohol, and has served in clinical use as a bronchoprovocative
agent since 1997 (191,220). Mannitol is commercially available as dry powder, which is
inhaled from gelatin capsules in increasing doses; up to a maximum of 18 mannitol doses
are inhaled during the challenge test. Lung function is assessed one minute after each
inhaled dose of mannitol (191,220). The challenge is completed with a documented
decrease of 15% in FEV1 or when the total dose reaches 635 mg  (220). The mechanism
whereby mannitol causes airway narrowing is thought to involve an increase in airway
osmolarity, which leads to the release of mediators from mast cells and neuronal cells
(220). Mannitol reportedly stimulates release of histamine from human lung mast cells and
basophils in vitro (191). Histamine initiates the bronchoconstriction following inhalation
of mannitol and the leukotriens sustain the effect. In vitro experiments have also shown
that mannitol releases protaglandin D2 and leukotriene E4 from human mast cells and
leukotriens from eosinophils (221). Studies have shown mannitol inhalation to release
prostaglandin D2 and leukotriene E4 in asthmatic patients and to minor extent in healthy
persons (221,222). Inhalation of mannitol induces airway refractoriness for several hours
(191), which may be do to tachyphylaxis at the level of airway smooth muscles rather than
to lower mediator production (191).
The original study on safety and efficacy found a good condordance between
responsiveness to hypertonic saline and mannitol in asthmatic and healthy subjects (223).
In  a  study  of  subjects  with  asthmatic  symptoms  but  no  confirmed  diagnosis  of  asthma,
mannitol showed similar sensitivity and specificity to that of methacholine in identifying
doctor-diagnosed asthma or EIB (224). Nevertheless, the concordance between the test
results in these study subjects was not as good as between the persons with a known
diagnosis of asthma and healthy controls (223).
The mannitol test has proved useful in optimizing inhaled doses of corticosteroid
(225,226). In a study of 9- to 16-year-old asthmatic children with moderate to severe
disease, mannitol test showed good reproducility and tolerance (227). Another study of
asthmatic children (6-16 years of age) found positive and negative predictive values of
68% and 89% for the mannitol test in identifying exercise-induced bronchoconstriction
(228). Furthermore, the mannitol test identified methacholine-positive 9- to 16-year-olds
children with asthma (229). All these pediatric studies utilized spirometry to assess lung
function.
Researchers investigating the mannitol challenge test with oscillometry in 8- to 21-
year-olds found a significant correlation between a decrease in FEV1 and an increase in R5
by IOS after the mannitol test (230). Use of forced oscillation technique to measure the
mannitol response in adult patients showed high sensitivity and repeatability (231). No
published studies have investigated the mannitol bronchoprovocation test with IOS in
preschool-age children.
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Table 6. Studies that have investigated the abilities of AHR tests to differentiate between
various pediatric patient groups and studies among preschool-age children.
Study Subjects Age, mean
(years)
AHR tests Results
Godfrey et al
1991 (209)
52 with asthma
22 other
chronic lung
diseases
19 controls
11.7
11.4
14.4
Methacholine and
exercise
spirometry
Asthmatics more
reactive in exercise test
Both groups responded
to methacholine
Avital et al
1995 (197)
51 asthmatics
21 pediatric
COPD
19 controls
13.0
11.1-13.7
14.0
Adenosine
Methacholine
Exercise
spirometry
Methacholine
distinguishes asthma
and COPD from
controls, but not from
one another
Exercise and adenosine
distinguished asthma
from other groups
Wilson et al,
1995 (198)
40 asthmatics 4.6 - 6.0 Methacholine
Hypertonic saline
IOS
No differences
between present or
previous wheezing or
the clinical severity
Malmberg et
al
2008 (182)
130 wheezy
children
79 controls
5.6
5.1
Exercise with IOS Exercise test with IOS
distinguished wheezy
children from controls
Liem et al
2008
215 asthmatics
197 controls
8.3-8.7 Methacholine
spirometry
Sensitivity for asthma
66%, specificity 64%
Suh et al
2011 (199)
122 asthmatics
(97 atopic and
25 nonatopic)
5.3 Methacholine
Adenosine
with modified
auscultation
technique
Atopic asthmatics had
greater AHR-to-
adenosine than did
nonatopics, no
difference in
methacholine
responses
Schulze et al
2012 (201)
48 asthmatic
children
5.3 Methacholine
spirometry and
IOS
R5 by IOS detected 70-
80% of patients who
responded in
spirometry
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2.4.3 Measuring small airway function
Small airways are defined as distal airways with a diameter of less than 2 mm (232)
and start around generation eight in the bronchial three (169,233). This distal airway area
is traditionally referred as a silent zone, but in recent years more evidence has
accumulated to support the importance of the small airways in the pathogenenesis and
clinical picture of asthma (233). The mucosal cross-sectional area is much larger in the
distal than proximal airways, which is also reflected in overall airway resistance (234).
Small airways dysfunction has been associated with noctural asthma, severe asthma,
exercise-induced obstruction, recurrent exacerbations, symptoms and responses to inhaled
corticosteroids (9,235,236).
Inflammation, hyperresponsiveness and remodeling can affect both the large and small
airways. Functional features of small airway dysfunction include the peripheral
heterogeneity of the ventilation, air entrapment and premature airway closure (237). Some
have also proposed that the peripheral airways response to bronchoconstrictors differs
among asthmatics (10,238). Studies have shown methacholine-induced changes in forced
vital  capacity,  which  are  thought  to  reflect  airway  closure  due  to  small  airways,  to  be
associated with asthma severity, steroid requirements and symptoms in adults(10).
Measuring  the  small  airways  is  challenging,  because  the  distal  part  of  the  lungs  are
relatively unaccessible. The conventional and most widely used methods for assessing
lung function, such as spirometry, are not optimal for investigating the distal airways.
Forced expiratory flow at 25% to 75% of forced vital capacity (FEF25-75) is considered as a
measure of the distal airways, but suffers from poor reproducibility (239). A retrograde
catheter of 2 mm in diameter was wedged into the bronchus to measure airflow resistance
in the distal airways in a landmark study of the small airways (232). High resolution
computed tomography (HRCT), used to visualize regional air-trapping in the distal
airways, and helium-oxygen breathing tests are also invasive and technically complicated
methods for investigating the peripheral airways (240,241). Multiple-breath nitrogen
wash-out (MBNW) and oscillation techniques are less invasive, yet still potentially
sensitive methods to measure the distal airways and can also serve in young children
(236).
The  impulse  oscillometry  (IOS)  indices  R5-20,  X5  and  AX  are  suggested  to  reflect  the
distal airways function (166). Resistance at low frequency oscillations, such as 5 Hz (R5),
is considered to be a measure of both the proximal and distal airways. Proximal
obstruction increases both R20 and R5, and isolated distal obstruction increases R5 more
than R20 (165). This phenomenon is called frequency-dependent change and is calculated
as the difference between R5 and R20 (R5-20) (165).
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2.4.3.1 Small airways and IOS in children
Although remodelling and peripheral disease were thought to affect only adults and
only  after  a  long  asthma  history,  these  structural  changes  already  seem  to  be  present  in
small children (242).
Only a few published studies have investigated measurement of the small airways in
children with IOS. Children who lost their asthma control had a higher baseline R5-20 and
reactance area (AX) than did children who maintained control during the control visit after
8-12 weeks (168). The same study group also showed an association between uncontrolled
asthma and small airways dysfunction (R5-20, X5, Fres and AX)  (243). Studies used IOS
to examine the effect of inhaled corticosteroid/long-acting beta-agonist combinations on
small-airway dysfunction in 12- to 45-year-olds (244). The investigators found that
inhalation of the combination of medicines initially improved the peripheral lung function,
as measured with R5-20 and AX in about five minutes. After four weeks’ regular use of
the combination, the initial effect diminished due to the improved pre-dose status of the
peripheral IOS parameters (244).
2.5 Airway inflammation
Airway inflammation is one of the key features of asthma and is characterized by the
presence of inflammatory cells and the release of inflammatory mediators into the airways
(8). Mast cells, eosinophils, T-cells (Th2, Th17 and Treg cells), neutrophils, dendritic cells
and endothelial cells can be activated in the asthmatic airways (245,246). Children with
asthma show higher eosinophilic counts in induced sputum than do healthy subjects (247).
Important mediators in asthma may involve interleukins IL-4, IL-5 and IL-13 (15,246).
The need to control inflammation in the airways has driven to a development of devices
that measure biological markers of airway inflammation. Because directly evaluating
airway inflammation with brochoalveolar lavage (BAL) and bronchoscopic techniques is
invasive, innovators have developed less-invasive techniques to evaluate asthmatic
inflammation.
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2.5.1 Fractional concentration of nitric oxide (FeNO)
2.5.1.1 Biology of FeNO in the airways
In the late 1980s the small molecule nitric oxide (NO) proved to be an important
endogeneous mediator of various functions in both health and disease (248). Nitric oxide
is a free-radical gas, which forms in the airways when L-arginine oxidates to L-citrulline
(Figure 2) (249). The reaction is then catalyzed by NO-synthases (NOS), which exist in at
least three different isotypes (8). The constitutive NO-synthase (cNOS) is activated by
intracellular rises of calcium after cellular activation (8). Mediators such as histamine,
leukotrienes, bradykinin, acetylcholine and platelet-activating factor can also activate
cNOS (8). cNOS is further divided into neuronal NOS and endothelial NOS. Inducible
NOS (iNOS) is induced by TNF-?, IL-1 and INF-? and  higher  iNOS  levels  occur  in
inflammatory states (250). Subjects with asthma have shown an increased iNOS in airway
epithelial cells (251), which may be due to increased transcription mediated by STAT-1
and nuclear factor-?B (252-254); iNOS is independent of calcium concentration (255).
NOSs are present in several various cell types. Endothelial NOS exists in the
endothelial cells of lung vessels, the epithelium of the bronchi, alveolar epithelial cells,
nasal mucosa and ciliary microtubules (8). Neuronal NOS occurs in the nerves that supply
vessels  and  smooth  muscle  in  the  airways  (8).  iNOS  has  been  found  at  least  in  type  II
alveolar epithelial cells, macrophages, fibroblasts, smooth muscle cells, neutrophils,
endothelial cells and mast cells (249,255). Some cells may express two or more NOSs
(255).
After forming in the airways, NO is exhaled, oxidized, reduced or complexed with
other molecules in the airways (255). NO is highly unstable and reacts easily with other
molecules. Combining with oxygen converts NO into nitrite (NO2) and nitrate (NO3).
Peroxynitrite consist of NO and super oxide (O2).  NO  can  react  with  cysteine  and
glutathione to form S-nitrosoproteins and S-nitrosothiols, which as along with nitrite can
release NO and carry or store NO (249).
The levels of NO in the nose and nasopharynx are much higher than those expired
from the mouth suggesting that, at least in healthy subjects, the upper airways are a major
contributor to exhaled NO (256). The level of nasal NO is lower in subjects with primary
ciliary dyskinesia (257).
Nitrogen oxides can serve distinct functions in the respiratory tract and vascular
system, such as smooth muscle relaxation and vasodilatation, platelet inhibition, ciliary
function, viral inhibition and neurotransmission (258,259). Although understanding of the
link between airway inflammation and NO remains to be incomplete, increasing evidence
supports the conception that measuring NO in the breath may serve as a measure of airway
inflammation at least in atopic asthma (260).
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Figure 2. Nitric oxide (NO) synthesis from L-arginine (255).
2.5.1.2 FeNO measurement
The first descriptions of endogeneous NO in exhaled human breath are from 1991
(261). Direct measurement of NO is difficult, because NO is labile in the presence of
oxygen. Moreover, NO is present only in small amounts (259).
The ERS/ATS statement on measuring exhaled nitric oxide in children was published
in 2001 (260), and recommendations for standardized procedures for the online and offline
measurements appeared in 2005 (262). Online and offline measurement techniques are
available and thanks to their noninvasive, repeatable, safe and instantaneous
characteristics, are also quite suitable for young children. Online methods refer to
techniques, which directly analyze exhaled gas and offline methods analyze exhaled gas
first collected in a reservoir. Both methods use single breath or tidal breathing, although
the single breath technique is recommended (8). The single breath method, however, is
difficult for young children under four years of age, because they are incapable of
performing the manoeuvers needed to complete the measurements (260,262). The feasible
options for the youngest children are the tidal-breathing techniques, which do not require
controlled breathing manoeuvers.
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FeNO is commonly assessed with the chemiluminescence method, which is based on
the detection of photons when NO reacts with ozone (8).  The Aerocrine NO Monitoring
System NIOX was approved for clinical application in patients in Europe in 2000 and by
the US Food and Drug Administration in 2003 (263). A photomultiplier tube detects the
photons released by the reaction of NO and ozone, and generates a voltage linearly
proportional to the amount of NO in the sample (263). The result is then expressed as a
fractional concentration of exhaled NO (FeNO), in parts per billion (ppb). The lower
detection limit of the chemiluminescence analyzers is < 1 ppb. A reliable measurement
requires a constant exhalation flow, which is why the system incorporates a dynamic flow
controller (264). ATS/ERS recommends an exhalation flow rate of 50 ml/s (262), which is
monitored by the pneumotachograph.
Another  method  for  measuring  NO  is  based  on  electrochemical  detection  (8).  This
technology is incorporated in hand-held devices, which are easily available outside the
specialized laboratories. These hand-held devices (e.g. NIOX MINO by Aerocrine) yield
similar results to the simultaneously measurements of stationary chemiluminescence
analyzers (265,266). The technique is also available for young children, but the lack of
visual  motivation  in  the  NIOX  MINO  analyzer  makes  it  more  difficult  to  perform  with
young child (267). The lower detection limit in this device is 5 ppb (www.aerocrine.com).
For FeNO assessment (260), a child should be seated and breath quietly for about 5
min in order to acclimatize. The inspired gas should contain less than 5 ppb NO. Subjects
should  exhale  against  a  resistance  of  5-20  cmH2O  to  close  the  velum  in  order  to  avoid
contamination of expired air by nasal FeNO. The subject inhales to near-total lung
capacity (TLC) and then exhales at a constant flow of 50 ml/s until reaching a plateau of ?
2 s during an exhalation of ? 4-6 s.
The Finnish height-adjusted reference values have been published for preschool-age
(180) and school-age children (268). FeNO values should always be interpreted in
consideration of the symptoms and factors that may affect the FeNO. Several algorithms
for the use of FeNO in children have been published and the FeNO value of 5-25 (-35)
ppb is considered normal for children (8,269).
2.5.1.3 Factors affecting FeNO
Several factors can influence the results of a FeNO measurement (Table 7). Height is
the best determinant of FeNO in healthy children (268). According to a Finnish study, the
FeNO increased from 7 to 14 ppb in the height range 120-180 cm(268). FeNO is also
significantly associated with atopy, age, height, weight and body surface area, but not with
gender in Caucasian children (8,268). The most important factors that increase the FeNO
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level are atopy, infections and age/height (8,270). Very low FeNO levels can be seen in
cystic fibrosis, HIV infection and primary ciliary dyskinesia (260).
Several studies have shown that smoking and ETS affect FeNO levels. FeNO levels
are lower in active smokers than in non-smokers (271,272). Moreover, acute exposure to
tobacco smoke reduces FeNO levels (271,272). The mechanisms by which active smoking
decreases FeNO level remain unclear. Tobacco contains high concentrations of NO and
may reduce FeNO via negative feedback on inducible NO synthase (272). Some
investigators have also speculated that active smoking downregulates IL-10 production
from macrophages and, consequently, attenuates Th2 and eosinophil responses (126).
Reports of the effect of ETS on FeNO level in healthy children have found no associations
(273,274). Studies of children with asthmatic symptoms have shown conflicting results,
however. A study of infants with respiratory symptoms found an association between
parental smoking and elevated FeNO levels (275). In contrast, a study of school-age
asthmatic children reported an association between a lower FeNO level and ETS exposure
(139,276). Several studies report no associations between ETS and FeNO levels in
children with respiratory symptoms (138,141,273,277).
Table 7. Factors influencing FeNO.
Confounding factor Effect on FeNO
Atopy Increase(268,278)
Height Increase with increasing height (268)
Age Increase(268,279)
Spirometry Transient decrease(280)
Exercise Transient decrease(280)
Bronchoprovocation tests Transient decrease (281)
Alcohol Transient decrease (282)
Caffeine Conflicting results(283,284)
Nitrate containing food Increase(285)
Active smoking Decrease(271,272)
Passive smoking Conflicting results(275,276,286)
Infection Increase (252,271)
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2.5.1.4 FeNO and young children
The first report on increased FeNO levels in adult patients with allergic asthma was
published in 1993 (287). Since then several studies have been conducted in both children
and adults. Some of these studies found a correlation between exhaled NO and eosinophils
in the induced sputum of adult asthmatics (288,289). FeNO was positively associated with
sputum eosinophils and eosinophilic cationic protein in children with corticosteroid-
treated asthma (290). In a study of difficult pediatric asthmatics, FeNO levels correlated
with bronchoscopic biopsy eosinophils in children who adhered to systemic prednisolone
treatment (291).
Studies on FeNO in relation to lung function, hyperreactivity, asthma diagnosis and
disease severity have yelded conflicting results. Atopic asthmatic school-age children
(median age 8.1 yrs) with previous symptoms had higher FeNO levels than did symptom-
free asthmatics or healthy controls (292). In 6- to 17-year-old asthmatics, FeNO was
correlated with blood eosinophils, IgE and ECP and methacholine challenge results, but
weakly with FEV1/FVC and bronchodilatation response and not at all with clinical
symptoms or PEF values (293). Most studies aiming to assess the relationship between
FeNO and lung function has failed to show such (8,278). Atopic status seems to be a
fundamental feature to be accounted for when interpreting FeNO results, and investigators
have suggested that FeNO is not necessarily directly linked to respiratory symptoms or
lung function (278).
Studies have explored FeNO in preschool-aged children. Because respiratory
symptoms are extremely common in early childhood, a non-invasive FeNO measurement
emerged as an attractive method for diagnosing and monitoring asthma in preschoolers.
However, FeNO values should always be interpreted with the knowledge of the patients’
current symptoms and possible influencing factors (Table 2).
A study from Israel succesfully differentiated two- to seven-year-old steroid-naive
asthmatic children from healthy and steroid-treated children with the off-line tidal
breathing method (294). Dutch investigators reported FeNO reference values for one- to
five-year-old healthy children with off-line FeNO assessment. This population showed a
mean FeNO of 7.1 ppb (295). A report of 4- to 27-month-old infants with recurrent lower
respiratory track symptoms found an association of FeNO with a maternal history of
asthma and increased airway hyperresponsiveness (296). Atopy, blood eosinophilia and
lung function showed no association with increased FeNO level. In 3.8- to 7.5-year-old
Finnish children, the FeNO level served to distinguish children with probable asthma from
controls and asthmatics receiving inhaled corticosteroids (180). A recent study of 75
children of four- to eight-year-olds found that increasing age, severe asthma and atopic
dermatitis were associated with higher FeNO levels (297).  A follow-up study examined
391 preschool-age children to determine whether higher FeNO at an early age could
predict asthma at school age (298). The investigators found higher FeNO values in
children with later asthma and proposed a new index for predicting asthma that includes
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FeNO. According this predictive index, children with higher scores ran a 58 % risk for
later asthma: the negative predictive value of this index was 78 %. A recent study reported
higher FeNO levels in 3- to 47-month-olds with wheezing episodes than in children with
cough only (299).
A Danish study warns against diagnosing asthma based on a dichotomized approach
with FeNO or AHR. They studied both asthmatic and symptom-free seven-year-olds and
found AHR and FeNO to be associated in both groups regardless of symptoms (300). In
addition, two published meta-analyses focused on FeNO-tailored asthma treatment
(270,301). Both reports concluded against recommending FeNO-guided asthma treatment,
because it fails to improve asthma control and may lead to increased daily doses of inhaled
corticosteroids with no meaningful improvement in clinical symptoms and lung function
(270,301). Several factors influence FeNO values, a fact that researchers must bear in
mind when interpreting the results.
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3. Aims of the study
Diagnosing asthma in preschool children is based mostly on clinical symptoms. New
objective methods for assessing asthma diagnosis in this age group are needed. This study
was designed to clarify the role of lung function, airway hyperresresponsiveness and
bronchial inflammation in young children with respiratory symptoms. The specific aims
were:
1. To determine whether young children were able to perform FeNO measurement
with a portable nitric oxide analyzer (Study I).
2. To examine the effect of risk factors such as parental smoking on lung function and
bronchial inflammation in young children (Study II).
3. To study airway hyperresponsiveness with the exercise, methacholine and mannitol
challenge tests in different patient groups using impulse oscillometry (Study III).
4. To evaluate small airways function during the methacholine challenge using impulse
oscillometry (Study IV).
53
4. Materials and methods
4.1 Study subjects
All the children were three to eight years old at the time of the studies and were evaluated
at the Skin and Allergy Hospital in Helsinki University Central Hospital. A schematic
illustration of the patients groups appears in Figure 3.
Figure 3. Schematic illustration of the study groups and main methods used.
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Study I
A total of 55 children participated in the study from October 2004 to February 2005.
Half of these children (n = 28) were referred to the hospital due to asthmatic symptoms.
They took part in a study that evaluated lung function in wheezy atopic young children
and non-atopic controls (182). Two of these children were using inhaled corticosteroids at
the time of the evaluation; all other children were free from asthma-control medication.
The other half of the children (n = 27) were age-matched children in good health with no
symptoms  or  signs  from  the  respiratory  tract.  They  had  participated  in  a  study  that
examined the effect of adenoidectomy with tympanostomy tubes in children with recurrent
or persistent otitis media at the age of 12 to 48 months (302). At the time of the present
study, they were healthy.
Study II
Children with suspected asthma (n = 105) were referred to the hospital during August
2002 and June 2005. The study children participated in a trial investigating the efficacy of
combining of salmeterol and fluticasone propionate over that of fluticasone propionate or
salmeterol alone in reducing airway inflammation in preschool children with multiple-
trigger wheezing (303). The children had a history of breathlessness or wheezing both
during and outside viral infections (multiple-trigger wheezing) and showed bronchodilator
responsiveness and/or exercise-induced bronchoconstriction as measured with IOS.
Patients were excluded if they presented with seasonal symptoms only, had experienced
signs of respiratory infection during the previous two weeks or had received inhaled or
systemic corticosteroids in the previous six months.
Their lung function was measured with IOS in the first visit to the study clinic. If they
fulfilled the inclusion criteria, the patients were invited to complete the study
investigations. At enrollment, the parents of the children completed a questionnaire, which
inquired the number of cigarettes smoked in the family per day and other background
information.
Studies III and IV
A total of 121 children participated in the study during the period from October 2009 to
February 2013. Any of the study children who were using regular asthma-control
medication stopped it four weeks before the lung function tests.
Of these children, 31 were referred to our hospital because for probable asthma due to
troublesome lung symptoms (denoted as TLS). The children suffered from chronic
coughing, exercise-related symptoms or recurrent wheezing. The median duration of
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symptoms was 11 months (range 2-36 months). Of the TLS children 13 (42 %) had
suffered from troublesome coughing, 12 (39 %) from wheezing and 6 (19 %) presented
with respiratory symptoms during exercise. The inclusion criteria for the study were: 1.
age four to six years 2. asthmatic symptoms (wheezing, coughing, dyspnea) 3.
satisfactorily completed exercise test by free running with IOS. The exlusion criteria were:
1. previous diagnosis of asthma 2. previous use of asthma control medication for over six
months. 3. jnhaled corticosteroids during the previous two months.
A total of 61 study children had suffered from wheezing in early childhood. They were
recruited for a follow-up study from a previous study that evaluated the effect of
montelukast on respiratory symptoms and lung function in wheezy infants (304). These
children had suffered from persistent or recurrent wheezing and/or dyspnea at the age of
six to 24 months and a doctor had diagnosed at least one of their wheezing episodes. This
group  was  called  as  early  wheezers  (EW).  In  total,  83  %  of  the  EW  children  wheezed
and/or had dyspnea both during and outside viral infections (multiple-trigger wheezing) at
the time of the previous study.
We recruited 15 age-matched children with a history of bronchopulmonary dysplasia
(BPD) during the neonatal period from the Helsinki University Central Hospital’s
Children’s  Hospital.  The  diagnosis  of  BPD  was  assessed  according  to  the  current
guidelines during the newborn period (4). The mean gestational age of these children was
27 (range 25-39) weeks, their mean birth weight was 940 (475-1350) g, the mean number
of surfactant boluses was 2 (1-6), the mean length of ventilator therapy was 26 (1-77) days
and the mean length of oxygen therapy was 98 (30-240) days.
Finally, 14 healthy age-matched subjects were recruited as controls: they had
participated in a study that evaluated the effect of adenoidectomy on respiratory symptoms
(302) and had no signs or symptoms of atopic disease or asthma and succesfully
performed the free running test and the methacholine challenge test.
4.2 Lung function and airway hyperresponsiveness assessments
4.2.1 Lung function
The children of the study groups II, III, and IV underwent lung function measurement
with IOS. Respiratory system resistance at 5 (R5) and 20 (R20) Hz as well as reactance at
5 (X5), 10 (X10) Hz were assessed as described previously (5,182,305). The frequency
dependence of resistance was calculated as the difference between the respiratory
resistance at 5 Hz and 20 Hz (R5-20) in Study IV. Responsiveness to the bronchodilator
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was assessed after an inhalation of 300 ?g of salbutamol. A positive response was defined
as an increase of 35% or more in R5 (5).
4.2.2 Airway hyperresponsiveness assessment
The children in studies II, III and IV performed exercise test. In addition, the methacholine
challenge was performed in studies III and IV and the mannitol challenge test in study III.
4.2.2.1 Exercise test
An outdoor free running test served as an exercise test (182). The children ran for six
to eight minutes at such exercise level that raised their heart rate (HR) to approximately
85-90% of their estimated maximum HR, as assessed with a hearth rate monitor (Vantage
NV,  Polar  Ltd,  Kempele,  Finland).  IOS  measurements  for  lung  function  were  taken  at
baseline and repeated at 1, 5, and 10 minutes after the exercise. A positive test result was
defined as an increase of 35% (in study II) and 40% (in studies III and IV) in R5. Finally,
the children inhaled 300 ?g salbutamol, administered via a Babyhaler, and the lung
function measurement was repeated 15 minutes after the inhalation.
4.2.2.2 Methacholine challenge test
The methacholine challenge test was applied as a dosimetric bronchial provocation test
modified for preschool children (306). First, we assessed the baseline R5 with IOS. After
that, we used an automatic, inhalation-synchronized dosimeter (Spira Electro 2, Spira
Respiratory Care Centre Ltd, Hämeenlinna, Finland) connected to a calibrated nebulizer
(Salter Labs 8900, Arvin, CA) to administer increasing doses of methacholine chloride.
The R5 was remeasured 90 seconds after each inhalation dose. A rapid dosage scheme
with five cumulative dose steps was applied by calculating the number of breaths with
nebulized methacholine. The procedure was continued until R5 decreased by 40% or the
subject received the maximum dose of methacholine. The dose of methacholine that
provoked the 40% decrease in R5 was determined from the dose-response curves
(175,307). The test result was considered positive, if the PD40R5 was < 400 ?g. This cut-
off is based on data from a study in which this same cut-off corresponded approximately
to the provocative dose of methacholine < 1 mg that decreased the forced expiratory flow
in  one  second  (PD20FEV1) by 20% (201). This result indicates significantly increased
AHR (308) and is predictive of active asthma in the follow-up into adolescence (202).
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4.2.2.3 Mannitol challenge test
The mannitol we used in the mannitol challenge test was dry powder (Aridol,
Pharmaxis Ltd, NSW Australia). A mannitol challenge test kit consists of one empty
capsule, two 5-mg capsules, two 10-mg capsules and eighteen 40-mg capsules. The
subject inhales the encapsulated mannitol through the Osmohaler in cumulative doses and
then holds his or her breath for five seconds. We checked the inhalation technique on
every child and measured peak inspiratory flow (PIF). IOS served to assess lung function
at baseline and 60 seconds after each mannitol dose (placebo, 5, 10, 20, 40, 80, 160, 160,
160 mg). We performed three consecutive IOS measurements at every step. The challenge
was continued until R5 increased by 40% or the subject received cumulative dose of 635
mg (230,231,307). A PD40R5 ? 635 mg was considered a positive test result based on the
established interpretation in adults (220).
4.3 FeNO measurements
The FeNO level was assessed in studies I, II and III. FeNO level was measured with the
stationary chemiluminescence-based analyzer NIOX (Aerocrine AB, Sona, Sweden). In
study  I,  we  used  NIOX and a  portable  electrochemical  NIOX MINO (Aerocrine  AB)  to
compare measurements between the two techniques.
We measured FeNO, according to ATS/ERS recommendations (262) and calibrated
the analyzers according to the manufacturer’s specifications. The test was performed
while the children were seated and without a nose clip. The children filled their lungs
completely with NO-free air; they then exhaled with a mean and instantaneous flow of 50
? 5 ml/s for at least six seconds.  Both devises automatically rejected the measurements
that not fulfill the criteria. Consecutive, acceptable paired measurements were recorded,
followed by calculation of the mean results and repeatability.
In study I, we first measured NIOX followed NIOX MINO measurements with an
interval 10 to 15 minutes between the measurements. The lowest detection limit with
NIOX is 2 ppb and in NIOX MINO 5 ppb. The analytical accuracy in NIOX is ? 2.5 ppb
for measured values < 50 ppb and ? 5% of the measured values > 50 ppb (263). With
NIOX MINO the analytical accuracy is ? 5 ppb up to a maximum of 15% of the measured
value (www.aerocrine.com).
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4.4 Urinary cotinine measurements
The urinary samples were collected from the children in study II during their second
visit to the study clinic. The samples (3 X 10 ml) were stored at -26?C until analyzed. We
used gas chromatographic method of Feyerabend and Russell to extract cotinine from
urine samples (309). As an internal standard, 200 ?g of 5-methylcotinine (100 ?g/l in
dichloromethane) was added and mixed with 200 ?g of urine. We added 100 ?g of 1,2
dichloroethane, 40 ?l of antifoam/phenol red mixture (20 mg phenol red/100 ?l  5  %
antifoam) and 600 ?l of sodium hydroxide solution (5 mol/l) and then centrifuged the
mixture. We then injected 2 ?l of this concentrated extract into a Hewlett-Packard FFAP
silica capillary column of an Agilent 7890A gas chromatograph equipped with an Agilent
blos bead nitrogen-phosphorus detector. Air and hydrogen served as detector gases, and
helium as a carrier gas. The current was 30 pA, and the detector temperature was 330?C.
The temperature programme in the oven was as follows: from 80?C to 120?C at 40?C/min,
from 120?C to 220?C at 12?C/min, and 220?C for 10 minutes. The lower detection limit of
the measurement was 0.7 ?g/l (309).
4.5 Atopy assessment
We  used  skin  prick  tests  (SPT)  to  screen  for  atopy  in  all  the  study  children  (SQ,  ALK,
Horsholm, Denmark). The following aeroallergens were tested: birch, timothy grass,
meadow fescue, mugworth, cladosporium herbarum, cat, dog, horse, cow and house dust
mite.  The  following  foods  were  tested:  egg,  milk,  fish,  wheat,  schrimp and  peanut.  SPT
was  considered  positive  if  at  least  one  of  the  tested  allergens  showed  a  wheal  with  a
diameter of ? 3 mm and the control solution gave a negative result.
4.6 Eosinophilic activity
In study III, the blood samples were also taken during the first or second visit to the study
clinic to assess eosinophilic cationic protein and eosinophilic count. The samples were
examined under routine laboratory methods in the laboratory of the Helsinki University
Central Hospital.
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4.7 Statistical analysis
Sample size
We calculated sample size for study III by using the intraclass correlation coefficient
(ICC). This method measures agreement between paired observations; in this study, we
evaluated the agreement between the methacholine and mannitol challenge tests and the
exercise test. Thus, the calculated sample size was 57.
The  sample  size  in  studies  I,  II  and  IV  was  based  on  the  number  of  available
measurements of lung function and FeNO level.
Study I
We analyzed agreement between the two FeNO devices with Bland-Altman plot and
included 95% confidence intervals for limits of agreement. The coefficient of the
repeatability (CoR) and the mean difference between the paired measurements served to
estimate the repeatability. We compared the mean FeNO values between the devices with
the student t-test and analyzed the results between the asthmatics and controls with the
unpaired student t-test. For the correlation analyses the FeNO values were log transformed
because the values were not normally distributed. Pearson correlation test was used for the
correlation analyses.
Study II
The  normality  of  the  value  distribution  was  tested  with  the  Shapiro-Wilks  test.  Non-
parametric tests were used, because the FeNO, cotinine and R5 values were not normally
distributed. Parental smoking was categorized in two different ways. First four different
categories were defined according to the smoking habits at home: no smoking, only
mother, only father, and both smoking. Second, the children were categorized according to
maternal smoking: yes/no. The Kruskall-Wallis test, the Jonckheere-Terpstra test or the
Mann-Whitney U-test were used to compare the categorical data. Correlation analyses
were made by Spearman correlation coefficient. A correlation coefficient of 0.1 was
considered small, 0.3 moderate, and 0.5 large (310). We used Chi-square test to compare
the two categorical datasets.
Study III
Because the data were not normally distributed, we used non-parametric tests. We used
the Kruskal-Wallis test and Mann-Whitney test to compare continuos data and used
Spearman’s correlation test to the correlation analysis. To study whether the methacholine
and mannitol challenge tests could identify EIB, we applied receiver-operator
characteristics (ROC) curves. An area under the curve (AUC) of 0.9-1 was considered
excellent, 0.8-0.9 good, 0.7-0.8 fair, 0.6-0.7 poor and 0.5-0.6 fail. BPD children were
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excluded from the analysis, because their underlying lung function disorder was
presumably different from that of the asthmatic children. Possible explanatory factors
were analyzed with binary logistic regression. The mannitol and methacholine challenge
tests and exercise test were included as dependent variables and skin prick test positivity,
parental smoking and the FeNO level served as covariates.
Study IV
We used nonparametric tests and the Kruskal-Wallis test and Mann-Whitney tests to
compare IOS indices R5, R20, R5-20, X5 and X10 at baseline and after the methacholine
challenge.
The statistical siginificance was set at a p < 0.05. We analyzed the data with SPSS, version
19.0 (SPSS, Inc, Chigaco, IL).
4.8 Ethics
The Ethics Committee of the Helsinki University Central Hospital (81/E7/02 and
337/13/03/03/2008) approved this series of studies. Finnish Medical Agency approved the
study (KLnro 246/2008 EudraCT 2008-007264-41).
Each parent provided his or her written, informed consent before their child took part in
the study.
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5. Results
The basic characteristics of the study populations appear in Table 8.
Table 8. Basic characteristics of the children in studies I, II, III and IV.
Study I Study II Study III and IV
Number of subjects 55 96 121
Female, n (%) 24 (44) 31 (32) 47 (39)
Age (y), mean
(range)
5.7 (3.9-8.5) 5.6 (3.9-7.9) 5.9 (3.7-8.1)
Height (cm), mean
(range)
115 (99-134) 115 (99-113) 116 (97-153)
Skin prick test
positivity, n (%)
30 (55) 72 (75) 46 (38)
Parental asthma, % 34 39
Symptoms 28 with asthmatic
symptoms
27 healthy controls
multiple-trigger
wheezing
31 with suspected
asthma
61 early wheezers
15 BPD survivors
14 healthy controls
5.1 FeNO measurements (Study I)
5.1.1 FeNO measurements with stationary and portable analyzers
Of the children in the study, 40 (mean age 6.1 years, range 4.1-8.5 years) were capable of
performing measurements with both FeNO analyzers (NIOX and NIOX MINO).
Measurements were more often successful with NIOX than with NIOX MINO (93% vs.
73%, p = 0.004), and the children who were unable to produce reliable FeNO values with
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MINO were younger than children with successful measurements. The success rates in
different age groups appear in Table 9.
The NIOX analyzer produced slightly higher FeNO values than did the NIOX MINO
analyzer (mean FeNO values 9.9. and 7.8 ppb, respectively, p = 0.002). However, the
measurements with the two devices correlated significantly (r = 0.972). The difference
between  the  devices  according  to  the  Bland-Altman  plot  was  1.1  ppb  with  limits  of  the
agreement between -4.4 and 6.7 ppb.
The mean FeNO with NIOX MINO was higher (14.3 ppb, median 9.5, range 2-48 ppb)
in children with asthmatic symptoms than in control children (median 6.0, range 1.0-15.0
ppb, p = 0.028, Figure 4). With NIOX, the difference between the groups did not reach the
statistical significance. In children with asthmatic symptoms the mean FeNO with NIOX
was 15 ppb (median 8.6, range 3.9-46.9 ppp) and in the control children 8.6 ppb (median
7.5, range 4.2-16.5 ppb, p = 0.071).
Table 9. Success rates in different age groups.
Age (years) Number of children NIOX NIOX MINO
3 - 4 15 11/15 (73%) 7/15 (47%)
5 - 6 31 31/31 (100%) 24/31 (77%)
7 - 8 9 9/9 (100%) 9/9 (100%)
All 55 51/55 (93%) 40/55 (73%)
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Figure 4. The median FeNO value measured with NIOX MINO in children with asthmatic
symptoms and controls. The box and whisker plot describes the first and third quartiles
(bottom and top of the boxes, 50% interquartile range, IQR). The band inside the box is the
median and the whiskers show the top and bottom 25% of scores. The circle represents an
outlier.
5.2 Environmental tobacco smoke (Study II)
5.2.1 Exposure to parental tobacco smoke
According to the questionnaires that the parents completed at the enrollment in the study,
43% of the children were exposed to ETS from parental smoking. The schematic
illustration of the parental smoking appears in Figure 5.
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Figure 5. Schematic illustration of the smoking status in families according to the
parental reports.
5.2.2 Parental reports and cotinine concentrations
The majority of the children (58%) had undetectable urinary cotinine concentrations.
Therefore, the median cotinine concentration was < 0.01 µg/l (range 0-17.1 µg/l). The
children with ETS exposure from parental smoking (median 2.0 µg/ml; range 0-17.1
µg/ml) had higher cotinine concentrations than did children with no parental smoking
(median < 0.01 µg/l; range 0-13.9 µg/l, p = 0.001) (Figure 6). The number of cigarettes
smoked by the parents and the urinary cotinine concentration correlated moderately (r =
0.404, p < 0.001). Urinary cotinine concentrations were highest in children with only the
mother smoking (n=13; median 4.1 µg/l; range 0-9.9 µg/l) and in children with both
parents smoking (n=14; median 4.6 µg/l; range 0-17.1 µg/l). We found a significant
difference between these two groups and children with non-smoking parents (n=55;
median < 0.01 µg/l; range 0-13.9 µg/l) or with only the father smoking (n=14; median <
0.01 µg/l; range 0-4.4 µg/l, p < 0.001).
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Figure 6. Urinary cotinine concentration grouped according to parental smoking. The box and
whisker plot describes the first and third quartiles (bottom and top of the boxes, 50%
interquartile range, IQR). The band inside the box is the median and the whiskers show the top
and bottom 25% of scores. The circles represent outliers.
5.2.3 FeNO level and exposure to tobacco smoke
The median FeNO z-score was significantly higher in children with a smoking mother
(median 3.3 SD; range 0.07-6.7 SD) than in children with a nonsmoking mother (1.9 SD;
range -0.62 - 6.53 SD, Figure 7). The FeNO level was lower in children with only the
father smoking (n = 14, median 11.2 ppb) and in children with nonsmoking parents (n =
55, median 12.9 ppb) than in children with both parents smoking (n = 14, median 25.4
ppb) or in children with only the mother smoking (median 23.3 ppb, p 0 0.46). The FeNO
z-score and the urinary cotinine concentration correlated (r = 0.22, p = 0.03). In addition,
the FeNO z-score and the number of cigarettes smoked in the family correlated (r = 0.22,
p = 0.034).
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Figure 7. FeNO z-score in children grouped by maternal smoking. The box and whisker plot
describes the first and third quartiles (bottom and top of the boxes, 50% interquartile range,
IQR). The band inside the box is the median and the whiskers show the top and bottom 25% of
scores. The circle represents an outlier.
5.2.4 Exposure to tobacco smoke and lung function
Lung function was assessed with IOS. The R5 z-score was higher in children with only the
mother smoking (median 0.61, range -1.4 - 3.7) than in children with a non-smoking
mother (median -0.008, range -2.1-4.8, p = 0.05, Figure 8). However, we found no
difference  in  R5  between  the  children  with  a  smoking  father  and  children  with  a
nonsmoking  father,  nor  did  we  find  correlation  between  the  R5  and  the  cotinine
concentration. We also found no correlation between the cotinine concentrations or
reported ETS and X5, X10, bronchodilatation effect or the extent of the exercise-induced
bronchoconstriction.
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Figure 8. R5 z-score according to maternal smoking. The box and whisker plot describes the
first and third quartiles (bottom and top of the boxes, 50% interquartile range, IQR). The band
inside the box is the median and the whiskers show the top and bottom 25% of scores. The
circles represent outliers.
5.2.5. Skin prick test positivity in relation to tobacco smoke exposure
Of  all  the  study  children  75%  tested  positive  on  the  skin  prick  test  (SPT).  At  least  one
positive reaction on the SPT was more common in children with ETS than in children with
no tobacco smoke exposure (85% vs. 68%, p = 0.043). The urinary cotinine concentration
showd no association with SPT positivity, eosinophilic count or eosinophilic cationic
protein.
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5.3 Airway hyperresponsivess (Study III)
Of all the 121 children, 23 (19%) were using regular asthma control medication at the time
of the study (none of the children in the TLS group, 34% of the children in the EW group,
13% of the children in the BPD group and none of the controls). All of the children took
the exercise test and methacholine challenge tests, and 97 children took the mannitol
challenge test. The FeNO level was assessed for 114 children.
5.3.1 Baseline lung function
The children in BPD group had a higher baseline R5 (median R5 z-score 1.5 SD, range -
1.4-6.2 SD) than did the children in other groups (TLS 0.04 SD; range -1.8-2.8 SD, EW
0.33 SD; range -1.8-3.5 SD, controls 0.02 SD; range -1.6-2.4 SD) (p = 0.023). We found
no significant differences between the other study groups.
5.3.2 Exercise test
Altogether 27 (22%) children tested positive on the exercise test. The positivity rates in
different patient groups appear in Table 10. The children in the TLS group showed a
higher R5 increase after exercise (median 62%; range -13-159%) than children in the EW
(median 19%; -16-111%), BPD (23%; -12-53%) or control groups (9%; 6-20%) (p <
0.001).
Table 10. Positivity rates for different airway hyperresponsiveness tests by patient groups.
All (n = 121) TLS (n = 31) EW (n = 61) BPD (n = 15) Controls (n = 14)
Exercise test
positive, n (%)
27 (22) 19 (61) 6 (10) 2 (13) 0
Methacholine test
positive, n (%)
84 (69) 24 (77) 47 (77) 10 (67) 3 (21)
Mannitol test
positive, n (%)
10 (11) 3 (10) 4 (7) 3 (20)
TLS = troublesome lung symptoms, EW = early wheezers, BPD = bronchopulmonary dysplasia
69
5.3.3 Methacholine challenge test
Altogether 86 (69%) of the study children tested positive on the methacholine challenge
test. The positivity rates in different patient groups appear in Table 10. The children with
symptoms were more reactive to methacholine than were the children with no symptoms.
However, the test was unable to differentiate the TLS, EW and BPD groups from each
others. The median PD40R5 in the TLS group was 90 µg, in the EW group 190 µg, in the
BPD group 210 µg and in the controls 590 µg. The methacholine challenge succesfully
distinguished between the TLS and control groups (p < 0.001), but not between the TLS
and EW groups (p = 0.263) or the TLS and BPD groups (p = 0.348). We found a
significant difference in PD40R5 between the EW and control groups (p < 0.001), but the
difference between the BPD children and controls did not reach statistical significance.
The children with positive exercise test results displayed more reactivity in the
methacholine challenge than did children with negative exercise test result (p = 0.004).
The receiver operator curve for methacholine challenge to identify EIB appears in Figure
9.
Figure 9.  Receiver-operator curves (ROC) for the methacholine and mannitol
challenge tests to identify exercise-induced bronchoconstriction. The area under the
curve (AUC) for methacholine was 0.70 (CI 0.58-0.82, p = 0.02) and for mannitol 0.58
(CI 0.43-0.73, p = 0.32).  Modified from Kalliola et al, the original for study III.
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5.3.4 Mannitol challenge test
Of the 88 children who took the mannitol test 10 (11%) tested positive. The positivity
rates for different patient groups appear in Table 10. The PD40R5  was  unable  to
distinguish between the study groups. The AUC for mannitol to identify EIB in the ROC
analysis was 0.58 (Figure 9) indicating poor ability to identify children with a positive
exercise test result.
The children who performed the mannitol challenge were also tested for peak
inspiratory  flow  (PIF)  before  the  challenge.  Their  median  PIF  was  within  the  optimal
range for the inhaler.  Poor cooperation resulted in the failure of the mannitol challenge
test in 9 cases. Coughing was the most common side effect during the challenge, and 65
children (73%) experienced coughing during the mannitol challenge. The median duration
of the mannitol challenge test was 46 minutes (range 25-66 min).
5.3.5 FeNO, atopy and AHR tests
A total of 114 children were able to perform the FeNO measurement successfully. The
FeNO z-score and the R5 increase during the exercise test correlated significantly (r =
0.43, p < 0.001, Figure 10). FeNO and the methacholine or mannitol challenge test results,
however, did not correlate significantly.
Children  with  current  TLS  had  higher  FeNO  z-scores  (median  2.5  SD)  than  did
children in the EW (1.0; -1.2-3.8), BPD (0.6; -0.9-2.1) or control (0.6; -1.2-2.3) groups (p
< 0.001).
Skin prick test positivity was found in 46 (38%) of the children. The extend of the EIB
was greater in atopic (median increase in R5 43%) than in nonatopic children (14%, p <
0.001, Figure 11). This increase was even more pronounced in children with current TLS.
In this group, the atopic children saw a median 69% increase in R5 after exercise test
compared to 17% increase among nonatopic children (p = 0.006). In addition, children
with atopy showed more reactivity in the methacholine challenge test than did nonatopic
children (median 130 µg vs. 250 µg, p = 0.02), but not in the mannitol challenge test.
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Figure 10. The correlation between the exercise-induced increase in R5 and the FeNO z-score.
Figure 11. R5 increase after the exercise test among atopic and nonatopic children. The box
and whisker plot describes the first and the third quartiles (bottom and top of the boxes, 50%
interquartile range, IQR). The band inside the box is the median and the whiskers show the top
and bottom 25% of scores. The circles represent outliers.
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5.3.6 Multivariate analysis
A positive result in skin prick test (OR 10.2, 95% CI 2.9-36.4, p < 0.001) and a higher
FeNO level (OR 1.1, 95% CI 1.0-1.2, p = 0.012) were associated with a positive result on
the  exercise  test.  We  found  no  such  associations  with  the  methacholine  or  mannitol
challenge tests.
5.4 Small airway function (Study IV)
All the selected oscillometry parameters were available for 109 of the 121 children. These
children were divided into three groups according to their result on the exercise test. The
EIB negative group was comprised children with R5 increase less than 40% on the
exercise test (n = 84), 13 children had moderate EIB (R5 increase from 40% to 80%) and
12 children showed severe EIB (R5 increase over 80%).
Children with severe EIB had more skin prick test positivity (100%) than did children
in the moderate EIB (77 %) or no-EIB groups (20%) (p < 0.001). These children were also
using more short-acting beta-agonists (92%) than were children with moderate (31%) or
no EIB (11%) (p < 0.001).
5.4.1 Baseline lung function
The children with moderate EIB had a higher R5 at baseline (median 0.92; range 0.72-
1.66) than did children with severe (0.78; 0.54-1.02) or no EIB (0.82; 0.52-1.84) (p =
0.048, Table 11). We found no significant differences between the groups in R5-20, R20,
X5 or X10.
5.4.2 Methacholine challenge test
Of all 109 children 68% had reactivity to methacholine indicated by an R5 increase 40%
or  more.  The  children  with  severe  or  moderate  EIB were  more  reactive  to  methacholine
than children with no EIB (Figure 12).
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Figure 12. Reactivity to methacholine in three different patient groups. No EIB = R5 increase
< 40 %, moderate EIB = R5 increase 40–80 %, severe EIB = R5 increase ?80 %. The box and
whisker plot describes the first and third quartiles (bottom and top of the boxes, 50%
interquartile range, IQR). The band inside the box is the median and the whiskers show the top
and bottom 25% of scores. The circles represent outliers.
5.4.3 IOS parameters after the methacholine challenge test
The median R5-20 increase after the methacholine challenge was higher in children with
severe EIB (median increase 2.61-fold; range 1.13-4.00) than in children with moderate
EIB (1.48; 0.7-2.84) or no EIB (1.74; -4.52-11.5, Table 11) (p = 0.036). In pairwise
comparison the difference between the severe EIB group and the non-EIB group reached
the statistical significance (p = 0.019, Figure 13).
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Table 11. IOS parameters before and after the methacholine challenge in three different
groups.
All ET-negative ET 40-80 % ET > 80 % p-value
Baseline R5 z-score,
median
0.16 (-3.0-
5.53)
0.18 (-3.0-
5.53)
0.41 (-1.14-
3.64)
-0.63 (-2.47-
0.62)
0.028
Baseline R20 (kPa/l/s),
median (range)
0.62 (0.44-
1.05)
0.63 (0.44-
1.05)
0.67 (0.55-
0.89)
0.59 (0.46-
0.81)
0.182
Baseline R5-R20
(kPa/l/s), median
(range)
0.19 (0.04-
0.89)
0.19 (0.04-
0.86)
0.25 (0.12-
0.89)
0.18 (0.05-
0.30)
0.064
Baseline X5 (kPa/l/s),
median (range)
-0.23 (-0.82-
0.42)
-0.23 (-0.82-
0.42)
-0.23 (-0.52-
0.21)
-0.20 (-0.3-
0.25)
0.221
Baseline X10 (kPa/l/s),
median (range)
-0.12 (-0.61-
0.0)
-0.12 (-0.59- -
0.01)
-0.14 (-0.61-
-0.05)
-0.12 (-0.18-
0.0)
0.151
R5 (fold increase),
median (range)
0.52 (-0.13
-1.09)
0.50 (-0.13-
0.90)
0.49 (0.28-
0.94)
0.46 (0.35-
1.09)
0.88
R5-20 (fold
increase), median
(range)
1.74 (-4.52
-11.5)
1.74 (-4.52-
11.5)
1.48 (0.70-
2.84)
2.61 (1.13-
4.00)
0.036
R20 (fold increase),
median (range)
0.12 (-0.22
-0.58)
0.12 (-0.22-
0.47)
0.12 (-0.14-
0.28)
0.12 (-
0.10-0.58)
0.79
X5 (fold increase),
median (range)
0.96 (-4.58
-3.91)
1.05 (-4.58-
3.91)
0.67 (-3.48-
2.62)
0.79 (-
2.80-2.82)
0.58
X10 (fold increase),
median (range)
2.13 (-0.50
-20.0)
2.17 (-0.50-
20.0)
2.07 (0.38-
3.71)
2.25 (0.92-
5.60)
0.34
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Figure 13. R5-20 increase after the methacholine challenge in children with severe EIB
and children with no EIB. Mann-Whitney test is used for pairwise unbound comparison.
No Bonferroni correction is used. The box and whisker plot describes the first and third
quartiles (bottom and top of the boxes, 50% interquartile range, IQR). The band inside the
box is the median and the whiskers show the top and bottom 25% of scores. The circles
represent outliers.
76
6. Discussion
In this study, we examined airway hyperresponsiveness, bronchial inflammation, small
airways function and the effects of parental smoking in young children with respiratory
symptoms.  According  to  present  results,  the  exercise  test  with  impulse  oscillometry  is  a
feasible method for evaluating preschool respiratory symptoms and can successfully
identify children with probable asthma. The methacholine challenge test is less specific,
but showed higher positivity rates in children with probable asthma, BPD history and
early wheezing symptoms than in controls. The mannitol challenge test was unable to
differentiate the patient groups. Children with severe exercise-induced
bronchoconstriction seem to have small airways dysfunction despite their young age. To
evaluate bronchial inflammation, a portable FeNO analyzer can serve to distinguish
asthmatics from the controls, but its success rate in young children is lower than with the
stationary device. Exposure to maternal smoking is a well-known risk factor for childhood
asthma. This study was able to show a connection between the children’s urinary cotinine
concentration and bronchial inflammation; furthermore, children with a smoking mother
had lower lung function than did children with a non-smoking mother.
6.1 Methodological considerations
6.1.1 Study populations
Of the 272 children (aged 3-8 years) examined in this study, 240 had obstructive lung
symptoms and 41 were healthy controls. The study children were homogeneous: the mean
ages in three study groups (Table 8) were 5.7, 5.6 and 5.9 years. The major strengths of
this study are that the children were well characterized and the lung function of every
child was assessed objectively with impulse oscillometry in studies II, III and IV. Children
using asthma-control medication stopped doing so for four weeks before the lung function
tests in order to exclude the masking effect of the inhaled corticosteroids.
The children in study II were multiple-trigger wheezers with normal basic lung
function but had bronchodilator responsiveness or exercise-induced bronchoconstriction,
which means that ascertaining the detrimental effect of the environmental tobacco smoke
cannot be directly generalized to the normal population. The groups of 15 BPD children
and 14 controls in study III were small which lowered the power of the study.
As noted earlier, several preschool wheezing phenotyping systems are provided mainly
based on the retrospective analysis, but none of them is optimal when evaluating children
with current respiratory symptoms. Regarding the cross-sectional study design, the various
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patient groups presented in this study do not completely follow the current definitions of
the preschool wheezing (3).
6.1.2 Lung function, airway hyperresponsiveness and FeNO measument
Lung function measurement with impulse oscillometry in young children is in routine
use in the laboratory of Physiology at the Helsinki University Central Hospital’s Allergy
Department. Finnish reference values for the interpretation of the results are available and
the measurements adhere to international guidelines (5,153,182).
No validated guidelines for the AHR tests with IOS exist, but the ATS/ERS statement
provides recommendations for the AHR assessments in preschool children (153). The
exercise test with IOS has shown the ability to distinguish wheezy children from controls
in the Finnish population (182) and the method is in routine use in our laboratory. An
increase of 35-40 % in R5 is widely accepted as a suitable endpoint in challenge tests with
IOS measurements (153,167,182).
We used a modified dosimetric method to carry out a methacholine challenge that
would be appropriate for preschool children (306). The method was easy to perform and
all the study children were able to complete it successfully. A cut-of value of 400 ?g for a
positive PD40R5 was chosen based on the data from Schulze et al (201). The value of 400
?g would correspond to a PD20FEV1 of < 1 mg, which indicates significant AHR (308).
The lower cut-off value for young children could more accurately distinguish between
asthmatic and healthy children.
The mannitol challenge was adhered to the published protocol (220). The mannitol
challenge test with IOS in school-age children has yielded comparable results to those of
the spirometric technique (230). A positive test result was defined as PD40R5 based on the
established interpretation in adults (220). The inhalation technique was verified prior to
the challenge, and all the study children passed the test. However, inhalation of up to 19
powder doses seemed demanding for children under school age. The control children did
not perform the mannitol challenge test, which is one of the limitations of the study.
However, given the low positivity rate on the mannitol challenge test in the present study,
the result would probably be no different even if we have tested control children as well.
We used the characteristics of the receiver operator characteristics curves (ROC) to
examine the ability of methacholine and mannitol tests to identify exercise-induced
bronchoconstriction. Neither of the tests showed good ability to identify EIB. The
assessment of asthma diagnosis in preschool-age children has no gold standard. However,
previous studies have shown that the exercise test with IOS can distinguish children with
current wheeze from healthy controls (182). According to the present study, the examined
AHR tests cannot serve to test surrogates for each other.
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FeNO was measured according to ATS recommendations (262); a well-experienced
nurse assisted us with the measurements. The devices automatically reject non-acceptable
exhalations. ATS/ERS recommends at least a 4 s exhalation for a child over four to five
years old (262); the present study used an exhalation flow of at least 6 s. The shorter
exhalation may improve the FeNO measurements in young children, and could have
improved the success rate of measurements taken with a portable device. Measurement
taken with the stationary NIOX analyzer was performed first, followed by the assessment
of FeNO with MINO after a 10 to 15 min interval. This may have affected the study result
through the learning effect, and could have lowered the success rate with MINO without
first performing the NIOX.
6.2.3 ETS monitoring
Exposure to tobacco smoke was monitored with the measurement of urinary cotinine
concentrations. The cotinine level measurement in body fluids offers a more objective
method for monitoring ETS exposure than the parental reports. The used gas
chromatographic method for the cotinine analysis has a lower detection limit of 0.7 ?g/l
(309). The recommended cut-off value for the second-hand tobacco smoke exposure is 0.5
?g/l, which means that some of the low cotinine levels may have gone undetected.
However, the difference between the 0.7 ?g/l and 0.5 ?g/l is minor and may have had no
significant influence on the study results.
6.2 Discussion of the main results
6.2.1 FeNO measurement with two analyzers in young children
Stationary FeNO analyzers are relatively expensive, require special expertise and are used
mostly in specialized clinics. The present study, which compared the feasibility, accuracy
and repeatability of using a portable, small and hand-held device (NIOX MINO) to a
stationary device (NIOX) in young children showed that the portable analyzer is a
practical tool for screening FeNO levels in young children. However, its use in this age
group is limited due to relatively poor accuracy, a higher lower detection limit and a lower
success rate than the stationary device. Still, both devices were able to distinguish between
higher FeNO levels in asthmatics and lower levels in healthy children.
The overall success rate with the stationary NIOX analyzer was 93% and with the
portable NIOX MINO 73%. These findings are in agreement with a report from Great
Britain in which investigators saw a 71% success rate with NIOX MINO in median nine-
year-old children (311). A study in Switzerland, which used a conventional analyzer and
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hand-held device to examine children of a mean age of 11.8, found that all of the study
children were able to perform the measurement successfully (265). In addition, they found
a between-method agreement within a clinically acceptable range. Children in the present
study were younger than those in earlier studies. The lack of visual motivation may be a
factor that influenced the lower success rate with the hand-held device compared to the
stationary device. With the stationary device the children are able to follow the balloon
animation on the computer screen, which helps with constant exhalation. In the portable
device, the pitch of the flow marker sound guides the exhalation. A retrospective analysis
that recently evaluated a portable MINO device in four- to seven-year-olds (297) found a
correlation between the FeNO and asthma severity but not with lung function. The study
did not report success rates with the portable device. Therefore, the success rates in the
present study are in line with those of the earlier reports. The younger the child, the more
difficult the performance of the hand held device seems to be.
The limits of agreement were wide in NIOX MINO in relation to the low FeNO levels.
The lower detection limit in NIOX MINO is 5 ppb compared to 1.5 ppb in NIOX
(www.aerocrine.com). This latter detection limit may be acceptable in adults and
asthmatic children, but in young healthy children it may be too high. In addition, the
manufacturer specifies a wider accuracy in MINO (values < 50 ppb, ? 5ppb) than in
NIOX (values < 50 ppb, ? 2.5 ppb). This may be important in lower FeNO levels (around
5 ppb), which frequently occur in young healthy children or in monitored pediatric
asthmatics. On the other hand, the clinical relevance of the FeNO values at these low
levels  may  be  only  modest.  In  conclusion,  the  study  suggests  that  NIOX  MINO  can  be
used as a screening tool in young children, but its feasibility at low FeNO levels is limited.
6.2.2 Exposure to tobacco smoke and respiratory health in preschool-age
multiple-trigger wheezers
This study, which investigated exposure to tobacco smoke with urinary cotinine
measurements, found a correlation between the FeNO z-score and urinary cotinine levels
in preschool-age children with multiple-trigger wheezing. In addition, a dose-response
relationship  was  shown  between  the  urinary  cotinine  level  and  the  number  of  cigarettes
smoked in the family. Children with a smoking mother had lower lung function and a
higher FeNO level than did children with a non-smoking mother.
Most studies have used parental reports to monitor ETS. However, people tend to
underestimate their bad habbits. Fortunately, ETS exposure can also be monitored by
measuring of cotinine in bodily fluids. Cotinine is a major nicotine metabolite with
anelimination half-time of approximately 20 hours, compared to two hours of nicotine,
which renders it useful for monitoring ETS over the previous three to four days (12).
Nicotine and cotinine metabolism may differ across individuals, which may influence the
cotinine levels (312). Moreover, the timing of the spot measurements in relation to
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tobacco smoke exposure can affect the outcome. However, measuring cotinine in bodily
fluids offers an objective and accurate tool for estimating tobacco smoke exposure.
In the present study, the children with a smoking mother or two parents smoking had
the highest urinary cotinine levels. This result is in agreement with the results of Japanese
researchers who showed higher urinary cotinine concentrations in children with smoking
mothers or two parents smoking than in children with only the father smoking or two non-
smoking parents (131). The overall median urinary cotinine concentration of the children
was low (median cotinine < 0.01 ?g/l). However, some of the non-exposed children
showed detectable cotinine concentrations possibly due to unreliable parental reports or
exposure to ETS outside the home. An American study examined cotinine levels in the
serum and saliva of 619 children who were hospitalized for asthma or wheezing (140). A
detectable cotinine concentration was associated with readmission to hospital.
Interestingly, 39% and 70% of those children whose caregivers reported no smoking had
detectable serum or saliva levels, respectively (140). Some of the exposure may come
from the third-hand smoking, which refers to the particulates that remain on the surfaces
and in the dust after cigarettes finished burning (313). These pollutants can be re-emitted
into the gas-phase or they can react with other environmental compounds to form harmful
products (313). Overall, the measurement of urinary cotinine concentrations seems to be a
realiable method for monitoring ETS exposure and offers additional information on
parental reports.
In the current study, 43% of the children were exposed to parental tobacco smoke.
According to the latest tobacco statistics, 14% of Finnish working-age women and 21% of
men smoke (105) and during the study years from 2002 to 2005 21% of women and 26%
of men were smokers (105). Consequently, exposure to ETS in the present study children
was rather high. All of these study children had lower respiratory tract symptoms, and
their exposure to parental tobacco smoke may have caused some of the symptoms and
deteriorated lung function among this group.
The  detrimental  effects  of  exposure  to  tobacco  smoke  on  children’s  health  are  well
established (11,122,314). Children are more sensitive to the negative effects of ETS than
are adults; children have higher respiratory volumes in relation to their body size than
adults, their metabolism, respiratory and immune systems are still developing and their
life-time expectancy is higher (313). Maternal smoking seems to influence children’s
health and lung function more than paternal smoking. This is suggested to be due to
detrimental effects of maternal smoking during pregnancy (110,122). One of the
limitations of the present study is that we had no data on the maternal smoking status at
the  time  of  the  pregnancy.  Separating  pre-  and  postnatal  ETS  exposure  is  difficult,  but
some evidence suggests that postnatal exposure increases respiratory symptoms in
children (119). Even if these children already had dimished lung function at birth, the
permanent postnatal exposure to tobacco smoke surely has negative effects on lung
function also. Moreover, children with a smoking mother had higher FeNO levels than did
children with no ETS exposure or with only the father smoking, indicating that the
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bronchial epithelium had an active inflammation at the time of the present study. Small
children seem to be close to their mothers even if their mothers report smoking outside. A
study that evaluated the effects of parental smoking on infants found eight times higher
urinary cotinine levels in infants with parents who reported smoking outside than in
children with non-smoking parents (315). Fathers probably smoke frequently at work or in
other places outside the home. Thus, maternal smoking, especially during pregnancy, is
more detrimental to a young child than is paternal smoking.
The patients in this study suffered from multiple-trigger wheezing and most of them
were atopic (75%). These features may be the predisposing factors behind the detrimental
effects of tobacco smoke exposure. Multiple-trigger wheezers are vulnerable to triggers
such as allergens and ETS (3). R5 was higher in children with a smoking mother than in
children with a non-smoking mother. A study of 41 preschool-age asthmatic children with
decreased lung function in the presence of ETS reported similar findings (135). A recent
report have showed that to locus of gene 17q21, which is associated with childhood
asthma,  has  a  sronger  effect  on  the  development  of  asthma  in  the  presence  of  maternal
smoking, thus suggesting interaction between the environment and genes via epistatic or
epigenetic mechanisms (1,130). Moreover, one of the studies from the Tucson cohort
found that parental smoking in infancy acts synergistically with the current smoking to
reduce lung function in early adulthood (316). Therefore, ETS is especially harmful for
subjects with a predisposition to asthma.
The negative influence of the maternal smoking on lung function was further
supported by the finding that the FeNO level was higher in children with a smoking
mother than in those with a non-smoking mother. In addition, the FeNO z-score and
urinary cotinine level correlated positively. Earlier studies of FeNO and ETS have shown
conflicting results, however. A study of young children with respiratory symptoms
showed an association between the reported parental smoking and increased FeNO levels
(275). In contrast, another study reported lower FeNO levels in ETS-exposed 8- to 18-
year-olds with inhaled corticosteroids than in those children with no ETS exposure (139).
A  study  of  school-aged  children  with  untreated  allergic  asthma  found  an  association
between decreased FeNO levels and parental smoking (276). A recently published report
showed no association between ETS exposure and FeNO or lung function in school-age
asthmatics (141). A study of school-age children found no association between the
cotinine levels and FeNO (138). However, our study children were younger than in most
of  the  other  studies.  To  conclude,  the  contradictory  results  in  studies  of  FeNO and ETS
may be due to heterogeneous and small study populations and age-dependent differences
in inflammatory responses.
The mechanism by which ETS raises the FeNO levels is unclear, but ETS may be an
inflammation-causing irritant in the airway mucosa, especially in children with untreated
multiple-trigger wheezing. Regular exposure to tobacco smoke is thought to change
inflammatory responses and enhance Th2 reactions (126). FeNO levels in active smokers
are lower than in non-smokers (271,272), possibly due to NO in tobacco smoke via the
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negative feed-back system on inducible NO synthase (317). In a study of Scottish
asthmatic bar workers, their FeNO levels decreased by 20% following smoke free
legislation (318). A study of infants reported that maternal atopy and prenatal ETS
exposure were associated with eleveated FeNO levels (319). Althought the current study
could not assess the association, several studies have shown that atopy increases FeNO
levels (8), which may be explained by the homogeneous study population with a high
prevalence of atopy (75% of the children), and rather high FeNO levels in all the children.
One of the strengths of the present study is that the population was relatively
homogeneous and that the children were not using asthma-control medication, which can
mask the inflammatory responses to various irritants. We studied confounding factors
such as parental atopy and animals at home and found no associations with increased
FeNO or decreased lung function. To summarize, ETS is suggested to alter inflammatory
responses on airways and enhance atopic reactions.
6.2.3 Airway hyperresponsiveness
The current study used impulse oscillometry (IOS) to investigate airway
hyperresponsiveness in preschool children. AHR was assessed with the exercise test, as
well as the methacholine and mannitol challenge tests. The tested children represented
various clinical patient groups. The study showed that the exercise test successfully
identified children with current troublesome lung symptoms (probable asthma), whereas
children with probable asthma, previous BPD and early wheezing symptoms tested
positive on the methacholine test, but not children without respiratory symptoms. The
mannitol test was unable to discern between the study groups.
Only a few studies have examined airway hyperresponsiveness in preschool-age
children, partly due to the difficulties in lung function measurements in this age group. In
addition, no standardized protocols for challenge tests are available for preschool children.
In the 1990s a couple of papers were published on these issues. One study reported that
the exercise test but not the methacholine challenge could differentiate asthmatic children
from  children  with  other  chronic  lung  diseases  (209).  Another  study  showed  that
methacholine  distinguished  asthma  and  pediatric  COPD  from  the  controls  but  not  from
one  another  (197).  Rather,  the  exercise  test  was  able  to  differentiate  asthmatics  from
subjects with other chronic lung diaseases. These results are in agreement with the present
findings.
In  the  present  study,  we  chose  IOS  parameter  R5  as  the  end-point  parameter  as  the
ATS/ERS  statement  recommends  (153).  IOS  is  easy  for  a  young  child  to  perform,  and
success rates as high as 80 to 90% are common in this age group (5,166). In this study all
the  children  were  able  to  perform  the  challenge  tests  with  IOS.  IOS  can  also  serve  to
assess AHR (320,321). In addition, research has shown that an increase in R5 and a
decrease in FEV1 in challenge tests correlate significantly (183,201). A German study that
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used both spirometry and IOS to examine hyperresponsiveness to methacholine in 48
preschool children (201) found that IOS also detected roughly 70-80% of those subjects
who responded to spirometry (201). Thus, IOS is a feasible method for assessing lung
function and AHR in young children.
The current study showed that 69% of all the study children were reactive to
methacholine, compared to 22% positivity in the exercise test. Children with probable
asthma showed more often positivity in the exercise test than did children with early
wheezing, BPD and controls. Instead, the methacholine challenge test result was often
positive in children with probable asthma, BPD and early wheezing but not in controls.
Methacholine is known to be highly sensitive, but less specific to asthma (189). The
mechanisms by which direct and indirect challenge tests act in the bronchus differ.
Methacholine acts directly on muscarinic receptors on the bronchial smooth muscle and
does not directly depend on airway inflammation (322). Instead inflammatory cells such
as eosinophils and mast cells, which release a variety of mediators under hypersosmotic
conditions, may mediate exercise-induced bronchoconstriction (210). Furthermore, some
some age-related and inherited features, may affect the results of airway
hyperresponsiveness tests in young children (229). FeNO levels and exercise test result
were associated, which may indicate the presence of eosinophilic inflammation, a
conclusion that is in line with earlier reports (186,323). FeNO was also able to distinguish
children with probable asthma from the other groups. To conclude, the exercise challenge
test  indentifies  active  asthma,  but  the  presence  of  AHR  for  methacholine  seems  to  be  a
less specific feature, at least in young children.
The children in the present study represented three groups with various clinical
characteristics. However, grouping of these children with lower respiratory symptoms is
difficult and some overlap between groups surely exists. Children with current
troublesome lung symptoms were referred to a hospital because of suspected asthma.
These children had no previous asthma diagnosis and their symptoms were started during
their third to sixth years of life; according to widely used wheezing phenotypes could be
called late-onset wheezers (2). The majority of these children (81%) were atopic, and 61%
had a positive exercise test result. Children with positive exercise test results were
diagnosed as asthmatics. This finding agrees with the concept that the exercise test is
highly specific for pediatric asthma (209).
Of  the  children  with  early  wheezing  disorder  who  had  wheezed  before  two  years  of
age, 83% had multiple-trigger wheezing type. At the time of the present study, however,
only 34% of them were using daily asthma control medication. This observation is in line
with the knowledge that early wheezers often recover and cease to wheeze before school
age. Early wheezing is associated with diminished lung function in infancy and maternal
smoking but not to atopy (2). Wheezing phenotypes during the preschool years commonly
change (2), the estimated prevalence of which is around 55% (1). In the present study,
children with EW were less reactive in the exercise test than were children with under
current suspicion of asthma. In contrast both groups showed high positivity rates in the
84
methacholine challenge test (77%), which agrees with the knowledge that the
methacholine challenge test is sensitive, but less specific for current asthma (6), and even
some (3 of 14) of the control children in this study exhibited reactivity in the methacholine
challenge test.
Thus, the clinical implication of positive methacholine test results in preschool
children is somewhat unclear. In Canada, 215 asthmatics and 197 healthy school-age
children were examined with the methacholine challenge test. The study showed that
methacholine may prove helpful when diagnosing asthma in atopic children, but is less
useful in non-atopics (203). Several cohort studies have used AHR to methacholine to
predict asthma or assess associations between different phenotypes and characteristics. A
British study examined over 6000 children at seven time points during their first seven
years of life to assess associations between the wheezing phenotypes and atopy, lung
function and airway hyperresponsiveness (18). The strongest associations were found
between the intermediate-onset wheezing phenotype and atopy (OR 8.36) and airway
hyperresponsiveness to methacholine (OR 1.76) (18). Late-onset wheezing also associated
with atopy and AHR, although more weakly than did intermediate-onset phenotype.
Therefore, positivity in the methacholine challenge may indicate a tendency for airway
hyperreactivity rather than be a marker of active asthma in young children.
Children with a history of neonatal bronchopulmonary dysplasia often exhibit
diminished lung function and increased airway hyperresponsiveness in later childhood and
in adulthood (55,57,174). The knowledge of AHR in BPD survivors at preschool age is
scarce. Researchers in Korea used the methacholine and adenosine challenge tests with
modified auscultation technique to examine prechool-age children with a history of BPD.
Their  results  agree  with  those  of  the  present  study,  in  that  the  BPD survivors  showed a
high positivity rate in the methacholine test, but low responsiveness to the indirect
adenosine test (59). The baseline R5 was higher in the BDP children in the present study
than in the children of other groups indicating poorer lung function. Furthermore, the BPD
survivors showed more reactivity in the methacholine challenge test than did the controls,
although the difference did not reach the statistical significance. This finding supports the
knowledge of the poor specificity of the methacholine challenge. Instead, the exercise test
result  failed  to  distinguish  between  the  children  with  earlier  BPD  and  controls  or  early
wheezing symptoms but did differentiate them from children with current asthma
suspicion. This result may be due to the presence of bronchial inflammation in children
with probable asthma and the lack of it in BPD survivors; lower FeNO level in BPD
survivors than in children with probable asthma supports this concept. To conclude, BPD
children showed hyperresponsiveness to methacholine but not to the exercise challenge.
Mannitol challenge test
The mannitol challenge test is an indirect challenge test recommended as a surrogate
for the exercise challenge (220,324), as it has shown results consistent with those of the
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exercise test in school-age children (228), good power to diagnose asthma (185) and linear
results with other bronchoprovocative tests (229). No previous studies have investigated
the mannitol challenge test in preschool-age children with IOS.
The present study entailed 97 mannitol provocation tests. The mannitol challenge test
was unable to differentiate patient groups from one another. Nine of these challenge tests
were incompleted, because of cooperative problems. The mannitol challenge test involves
inhaling up to a maximum of 19 doses of encapsulated mannitol powder if the entire
protocol  is  completed.  Although  all  of  the  study  children  were  able  to  surpass  the  peak
inhalation test  before taking the challenge test,  inhalating 19 powder doses seemed to be
excessive for children of this age as repeated inhalations may cause impairment in
inspiratory effort. As a result the powder may not have reached the peripheral airways. In
addition, 75% of the children experienced coughing during the mannitol challenge test,
which most of the children considered rather discomforting. Therefore, the results of the
present study do not favour the use of the mannitol challenge test in young children.
6.2.4 Small airways function in relation to asthma severity
In the present study, we evaluated small airways function during the induced
bronchoconstriction using impulse oscillometry. The study children were divided into
three groups according their test results in the exercise challenge. The main finding was
that severe exercise-induced bronchoconstriction was associated with small airways
dysfunction and more frequent use of short-acting beta-agonists. We are aware of no
earlier studies that have examined small airways function during a bronchoprovocative
test in young children.
Exercise-induced asthma is a specific feature of childhood asthma (209), and free
running is a natural way to induce asthmatic symptoms in preschool-age children.
Assessment of asthma severity based on lung function assessment is challenging in young
children. In the present study, asthma severity was defined by the extent of exercise-
induced change in IOS R5 during the free running test. This change has been shown to
correlate with the decrease in FEV1 in school-age children (325,326) and adults (183,327).
An increase of 35-40% in R5 in the challenge test is widely considered an abnormal
response (167,182,237). The categorization was made analogously to common guidelines
of  EIB as  assessed  with  spirometry  (204).  Therefore,  the  R5 increase  from 40% to  80%
was considered moderate EIB and an increase over 80% as severe EIB.
Although small airways dysfunction is considered important underlying feature of
various asthma symptoms and severity, the assessment of perfipheral airways function has
no gold standard (169).  Airway inflammation, hyperresponsiveness and remodeling can
affect the whole bronchial tree (169). The peripheral heterogeneity of the ventilation, air
trapping and premature airway closure are considered as functional features in small
airways dysfunction (237). Forced expiratory flow at 25% and 75% of forced capacity, as
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measured with spirometry, is considered to be a marker of the peripheral airways, but has
poor reproducibility (239,328,329). Some of the techniques for measuring small airways
are invasive and complex to perform (240,241). Impulse oscillometry and multiple-breath
nitrogen wash-out methods are non-invasive, and IOS is easily available also to young
children.  The  effect  of  large  airways  cannot  be  exluded  in  most  of  the  small  airway
measurements, so one should always interpret the results with caution (169).
Therefore, impulse oscillometry is proposed as a useful technique for assessing
peripheral airways function (168,330) due to its ability to measure the frequency
characteristics of respiratory mechanics (331). With increasing frequency and with
heterogenous time constants in the peripheral airways due to redistribution of flows,
studies have shown effective resistance and compliance in the lungs to decrease (331).
Adult patients show this pattern, but mostly at frequencies below 5 Hz (332). The present
study  could  assess  the  association  between  the  increased  R5-20  and  severity  of  asthma.
Although the frequency dependence of resistance above 5 Hz by the forced oscillation
technique may reflect artifactual airway shunting (333), it cannot alone explain the finding
of the present study. Thus, the present results suggest that children with severe EIB have
small airways dysfunction as measured by frequency-dependent resistance in IOS.
Oscillometric parameters X5 (reactance at 5 Hz) and AX (reactance area) are also
considered markers of small airways function, as explained by the changes in the elastic
properties of the respiratory system during ventilation heterogeneities with airway closure
or near closure (334). The current study could assess no association between the reactance
parameters and asthma severity, possibly due to challenges in impedance assessment at
low frequencies in young children with possible artifacts in the higher harmonics of the
fundamental breathing frequency (335). An Australian study found changes in reactance
after methacholine challenge to be a more sensitive marker for a small airways obstruction
than changes in resistance parameters in adults (236). Therefore, the present study could
assess no association between the reactance indices and asthma severity.
Recent pediatric studies have shown that the baseline IOS indices R5 and AX
predicted loss of asthma control more accurately than did spirometry (168,243). Another
investigation found that asthma patients with peripheral airway dysfunction, as measured
by FEF25-75 had more severe AHR independently of the FEV1 level (336). An Italian
study was able to assess an association between the R5, R5-20 and X5 and the magnitude
of the hyperresponsiveness to methacholine in school-age children and adults (337).
However, studies of small airways function in children are rare.
We chose to assess small airways function during the methacholine challenge because
similar investigations in adults have found connections between the signs of peripheral
airway dysfunction and asthma severity (10,238). The present findings suggest a similar
phenomenon occuring in young children with obstructive symptoms. The present results
suggest that the baseline lung function measurement in young children seems to be a less
sensitive marker for peripheral airway dysfunction. Two bronhcoscopic studies aimed to
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examine small airways function during bronchoprovocation test (338,339). The first study
found that  higher  small  airway resistance  at  baseline  was  associated  with  greater  airway
hyperresponsiveness to methacholine (339). The second study reported a faster increase in
peripheral airway resistance in asthmatics than in healthy persons after histamine
challenge (338). Furthermore, investigators from the UK reported an association between
small airways obstruction with IOS during methacholine challenge and dyspnea
perception in adult asthmatics (181). In addition, Dutch researchers found less peripheral
obstruction as measured with IOS during the methacholine challenge in asymptomatic
adults with AHR than in symptomatic subjects (330). According to the present results, the
small airways dysfunction may present even in young asthmatic children.
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7. Future considerations
According to the present study, exercise test with IOS is a feasible method for
examining respiratory symptoms in young children. Methacholine challenge with IOS is a
promising option for the assessment of bronchial hyperresponsiveness also in young
children. However, the cut-off value of this test may need to be further evaluated in larger
studies and may be lower than in older children and adults.  The clinical  implication of a
positive response in methacholine challenge in this age group remains unanswered, thus
warranting further research. Earlier studies have shown associations between the
childhood bronchial hyperresponsiveness to methacholine and later asthma (18), but the
evidence of the clinical relevance of this AHR to the present symptoms at preschool age is
lacking. A further challenge in interpreting the direct AHR test results is the lack of a gold
standard for asthma diagnosis in preschool children.
The findings of the mannitol challenge test in the present study discourage the use of
this test in the assessment of bronchial hyperresponsiveness in preschool children. A
shorter protocol may enhance the feasibility of the test in this age group, thereby making it
easier to carry out.
The FeNO measurement can also serve to estimate airway inflammation in preschool
children. The development of new hand-held FeNO analyzers could facilitate their usage
in young children. The FeNO level seems to reflect eosinophilic inflammation in atopic
asthmatics. However, the FeNO level is not recommended for use in tailoring asthma
medication. In selected individuals, its assessment may help to monitor adherence to
treatment and to characterize the asthma phenotype. For research purposes the FeNO
assessment seems to be a feasible method for monitoring airway inflammation even in
young children.
Tobacco smoke and exposure to tobacco smoke are known to harm health in many
ways. Interestingly, the elevated risk for asthma conferred by known childhood asthma
gene loci is further pronounced by environmental tobacco smoke in the early years of life
(130). The upcoming years will likely see an increase in our knowledge of the gene-
environmental interactions and the enhancement of our tools to modify early wheezing
outcomes.
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8. Conclusions
Estimating bronchial inflammation with a portable FeNO analyzer is a feasible option in
children over four years old, especially when it comes to distinguishing between
asthmatics and the healthy. However, it is more difficult to use with preschool-age
children than the older, stationary device. Moreover, the hand-held analyzer has a higher
lower detection limit and poorer accuracy at low FeNO levels, which limits its use in
young children.
We used parental reports and children’s urinary cotinine concentrations to examine
exposure to parental tobacco smoke. Urinary cotinine concentrations closely reflected
parental reports of their smoking habits. Furthermore, the FeNO z-score and urinary
cotinine concentrations correlated. Exposure to tobacco smoke by a smoking mother was
connected to reduced lung function and increased bronchial inflammation in young
children with multiple-trigger wheezing, yet paternal smoking showed less impact.
The  results  of  this  study  showed  that  bronchial  challenge  tests  with  impulse
oscillometry can serve to examine airway hyperresponsiveness in young children. The
exercise test performed as a free running test succesfully identified children with probable
asthma. The methacholine challenge test showed lower specificity than did the exercise
test, but yielded higher positivity rates in children with probable asthma, BPD and early
wheezing symptoms than in healthy controls. Therefore, the finding suggests that the
methacholine challenge may serve in assessing airway hyperresponsiveness even in young
children, but the cut-off value for this age group may need to be re-evaluated. In addition,
the clinical value of the positive methacholine challenge test in this age group remains
unclear. The results of the mannitol challenge test discourage its use in preschool-age
children.
We found small airways dysfunction in children with severe exercise-induced
bronchoconstriction. The result was further supported with the finding that children with
severe EIB were using short-acting beta-agonists more frequently than were children with
no EIB or moderate EIB. The results postulate that the small airways may play an
important role even in young children with severe asthma.
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